Methods and materials for identifying and treating senescence / age-related diseases

By employing PD-L2 as a biomarker and therapeutic target, senescence-related diseases can be accurately identified and treated, effectively addressing the accumulation of senescent cells and associated age-related conditions through the use of anti-PD-L2 and senolytic agents.

WO2024249938A1PCT designated stage expired Publication Date: 2024-12-05MAYO FOUNDATION FOR MEDICAL EDUCATION & RESEARCH
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/032113
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-07-07
Filing Date
2024-05-31
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Current methods fail to effectively identify and treat senescence-related diseases, as the immune system's impaired ability to clear senescent cells leads to their accumulation, contributing to age-related conditions such as cancer, cardiovascular disease, and metabolic disorders, and existing therapies may inadvertently promote tumor growth by inducing senescence in cancer cells.

Method used

The use of secreted Programmed Cell Death 1 Ligand 2 (PD-L2) as a biomarker for identifying senescence-related diseases and as a therapeutic target, involving the administration of anti-PD-L2 agents, senolytic agents, anti-TNFα therapies, NF-κB inhibitors, and MMP inhibitors to reduce senescent cell burden.

Benefits of technology

This approach allows for accurate identification and effective treatment of senescence-related diseases by reducing PD-L2 levels, thereby alleviating age-related conditions and improving metabolic health by targeting and clearing senescent cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000048_0001
    Figure IMGF000048_0001
  • Figure IMGF000062_0001
    Figure IMGF000062_0001
  • Figure IMGF000063_0001
    Figure IMGF000063_0001
Patent Text Reader

Abstract

Methods and materials for identifying and treating senescence and senescence-related and / or age-related diseases are provided herein. For example, this document provides methods and materials for using secreted PD-L2 to identify senescence / age-related diseases, as well as methods for using secreted PD-L2 as a therapeutic target for senescence / age-related diseases.
Need to check novelty before this filing date? Find Prior Art

Description

[0001]Attorney Docket No.07039-2219WO1 2023-151 METHODS AND MATERIALS FOR IDENTIFYING AND TREATING SENESCENCE / AGE-RELATED DISEASES CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority from U.S. Provisional Application Serial No. 63 / 525,480, filed July 7, 2023, and U.S. Provisional Application Serial No.63 / 470,068, filed May 31, 2023. The disclosures of the prior applications are considered part of (and are incorporated by reference in) the disclosure of this application. SEQUENCE LISTING This application contains a Sequence Listing that has been submitted electronically as an XML file named “07039-2219WO1.XML.” The XML file, created on May 29, 2024, is 20,480 bytes in size. The material in the XML file is hereby incorporated by reference in its entirety. TECHNICAL FIELD This document relates to methods and materials for identifying and / or treating senescence and senescence-related / age-related diseases. For example, this document relates to methods and materials for using secreted Programmed Cell Death 1 Ligand 2 (PD-L2) to identify senescence / age-related diseases, as well as methods and materials for using secreted PD-L2 as a therapeutic target for senescence / age-related diseases. BACKGROUND Senescent cells are cells that have stopped dividing due to damage or stress, but that remain alive and are metabolically active. Senescent cells exhibit distinct changes in their gene expression patterns, including the upregulation of a pro-inflammatory signaling pathway known as the senescence-associated secretory phenotype (SASP). The SASP involves secretion of various cytokines, chemokines, and growth factors, which can have both beneficial and deleterious effects on neighboring cells and tissues. Normally, senescent cells are cleared from the body by the immune system. With aging, Attorney Docket No.07039-2219WO1 2023-151 however, the immune system can become impaired, leading to a reduced ability to clear senescent cells. As a result, senescent cells can accumulate in tissues and organs, contributing to age-related diseases such as cancer, fibrosis, obesity, metabolic dysfunction, cardiovascular disease, and neurodegenerative disorders. In some cases, anti-cancer therapies result in a subset of surviving cancer cells that undergo therapy- induced senescence (TIS). Senescent cancer cells can modify the intratumoral microenvironment to favor immunosuppression and, thereby, tumor growth. SUMMARY This document provides methods and materials for identifying mammals having, or being likely to have, a senescence-related disease or condition (e.g., a senescence- related cancer, cardiovascular disease, neurodegenerative disease, pulmonary disease, chronic inflammatory disease, liver disease, kidney disease, eye disease, skin disease, vascular disease, musculoskeletal disorder, or metabolic disorder, or a senescence-related condition such as immune system dysfunction, osteoarthritis, type 2 diabetes, or age- related hearing loss). For example, this document provides methods and materials for assessing the amount of PD-L2 (e.g., secreted PD-L2) in a biological sample (e.g., a biological fluid sample) from a mammal, and when the level of PD-L2 in the sample is elevated relative to a control level of PD-L2, identifying the mammal as having, or being likely to have, a senescence-related disease or condition (e.g., a senescence-related cancer, cardiovascular disease, neurodegenerative disease, pulmonary disease, chronic inflammatory disease, liver disease, kidney disease, eye disease, skin disease, vascular disease, musculoskeletal disorder, or metabolic disorder, or a senescence-related condition such as immune system dysfunction, osteoarthritis, type 2 diabetes, or age- related hearing loss). This document also provides methods and materials for assessing the effectiveness of a treatment for a senescence-related disease or condition. For example, this document provides methods and materials for assessing the amount of PD- L2 (e.g., secreted PD-L2) in biological samples (e.g., biological fluid samples) obtained from a mammal before and after treatment of the mammal for a senescence-related disease or condition (e.g., a senescence-related cancer, cardiovascular disease, Attorney Docket No.07039-2219WO1 2023-151 neurodegenerative disease, pulmonary disease, chronic inflammatory disease, liver disease, kidney disease, eye disease, skin disease, vascular disease, musculoskeletal disorder, or metabolic disorder, or a senescence-related condition such as immune system dysfunction, osteoarthritis, type 2 diabetes, or age-related hearing loss), and determining that the treatment was effective when the amount of PD-L2 in the sample obtained after treatment is lower than the amount of PD-L2 in the sample obtained before treatment, or determining that the treatment was not effective when the amount of PD-L2 in the sample obtained after treatment is not lower than the amount of PD-L2 in the sample obtained before treatment. In addition, this document provides methods for treating a senescence- related disease or condition (e.g., a senescence-related cancer, cardiovascular disease, neurodegenerative disease, pulmonary disease, chronic inflammatory disease, liver disease, kidney disease, eye disease, skin disease, vascular disease, musculoskeletal disorder, or metabolic disorder, or a senescence-related condition such as immune system dysfunction, osteoarthritis, type 2 diabetes, or age-related hearing loss) in a mammal. For example, this document provides methods that include administering, to a mammal having a senescence-related disease or condition (e.g., a senescence-related cancer, cardiovascular disease, neurodegenerative disease, pulmonary disease, chronic inflammatory disease, liver disease, kidney disease, eye disease, skin disease, vascular disease, musculoskeletal disorder, or metabolic disorder, or a senescence-related condition such as immune system dysfunction, osteoarthritis, type 2 diabetes, or age- related hearing loss) and identified as having a biological sample containing an elevated level of PD-L2 (e.g., secreted PD-L2), (a) an anti-PD-L2 agent, and (b) an anti-TNFα therapy, an NF-κB inhibitor, or an anti-TNFα and an NF-κB inhibitor. In some cases, this document provides methods that include administering, to a mammal having a senescence-related disease or condition (e.g., a senescence-related cancer, cardiovascular disease, neurodegenerative disease, pulmonary disease, chronic inflammatory disease, liver disease, kidney disease, eye disease, skin disease, vascular disease, musculoskeletal disorder, or metabolic disorder, or a senescence-related condition such as immune system dysfunction, osteoarthritis, type 2 diabetes, or age-related hearing loss) and identified as having a biological sample containing an elevated level of PD-L2 (e.g., secreted PD-L2), Attorney Docket No.07039-2219WO1 2023-151 (a) an anti-PD-L2 agent, a senolytic agent, or an anti-PD-L2 agent and a senolytic agent, and (b) an MMP inhibitor, a gamma secretase inhibitor, or an MMP inhibitor and a gamma secretase inhibitor. As demonstrated herein, PD-L2 was identified as being highly upregulated across multiple types of senescent human and murine cells. The results provided herein also demonstrated that senescent cells secrete PD-L2, and that PD-L2 secretion is regulated by proteolytic cleavage, through the NF-κB pathway, and also by the miR-17-92 cluster. Moreover, increased levels of sPD-L2 were observed in senescent associated pathologies, and senolytics were found to target PD-L2 high expressing senescent cells. In addition, older PD-L2 knockout mice exhibited reduced senescent cell accumulation, PD-L2 knockout mice displayed improved metabolic health, and differences in survival were observed between aged male and aged female mice with wild type or knocked out PD- L2. In humans, sPD-L2 levels were found to be higher in plasma samples from older subjects than in plasma samples from younger subjects, and sPD-L2 levels also were found to be higher in plasma samples from obese subjects than in plasma samples from healthy subjects. The higher levels of circulating human sPD-L2 may act as a decoy and hinder effective anti-PD-L2 immunotherapy. In some cases, combining anti-PD-L2 antibodies with MMP inhibitors that decrease shedding of the PD-L2 ectodomain into the circulation may overcome this limitation, as may anti-PD-L2 vaccines. Having the ability to identify mammals as having senescence-related diseases and conditions e.g., a senescence-related cancer, cardiovascular disease, neurodegenerative disease, pulmonary disease, chronic inflammatory disease, liver disease, kidney disease, eye disease, skin disease, vascular disease, musculoskeletal disorder, or metabolic disorder, or a senescence-related condition such as immune system dysfunction, osteoarthritis, type 2 diabetes, or age-related hearing loss) can allow those mammals to be properly identified and treated in an effective and reliable manner. For example, the treatments provided herein (e.g., an anti-TNFα therapy and / or an NF-κB inhibitor in combination with an anti-PD-L2 agent, or an MMP inhibitor and / or a gamma secretase inhibitor in combination with an anti-PD-L2 agent and / or a senolytic agent) can be used to treat patients having cancer or other senescence-related diseases or conditions, Attorney Docket No.07039-2219WO1 2023-151 particularly when those patients are identified as having an elevated level of PD-L2 (e.g., secreted PD-L2). In general, one aspect of this document features methods for classifying a mammal as having, or being likely to have, a senescence-related disease or condition. The methods can include, or consist essentially of, detecting an elevated level of a secreted PD-L2 polypeptide in a biological fluid sample obtained from a mammal, and classifying the mammal as having the senescence-related disease or condition. The mammal can be a human. The senescence-related disease or condition can be a senescence-related cancer (e.g., a melanoma, a pancreatic adenocarcinoma, an osteosarcoma, a squamous cell carcinoma, a breast cancer, or a head and neck squamous cell carcinoma). The senescence-related disease or condition can be selected from the group consisting of cardiovascular diseases, neurodegenerative diseases, pulmonary diseases, chronic inflammatory diseases, liver diseases, kidney diseases, eye diseases, skin diseases, vascular diseases, musculoskeletal disorders, metabolic disorder, immune system dysfunction, osteoarthritis, type 2 diabetes, and age-related hearing loss. The biological fluid sample can be a whole blood, plasma, or serum sample. The elevated level of the secreted PD-L2 polypeptide can be as compared to a reference level of the secreted PD-L2 polypeptide present in biological fluid samples from controls known not to have the senescence-related disease or condition. The detecting can include using an anti-PD-L2 antibody to detect the elevated level of the secreted PD-L2 polypeptide. In another aspect, this document features methods for treating a mammal having a senescence-related disease or condition. The methods can include, or consist essentially of, (a) identifying a mammal as having a biological fluid sample with of an elevated level of secreted PD-L2; and (b) administering to the mammal a treatment for the senescence- related disease or condition. The mammal can be a human. The senescence-related disease or condition can be a senescence-related cancer (e.g., a melanoma, a pancreatic adenocarcinoma, an osteosarcoma, a squamous cell carcinoma, a breast cancer, or a head and neck squamous cell carcinoma). The senescence-related disease or condition can be selected from the group consisting of cardiovascular diseases, neurodegenerative diseases, pulmonary diseases, chronic inflammatory diseases, liver diseases, kidney Attorney Docket No.07039-2219WO1 2023-151 diseases, eye diseases, skin diseases, vascular diseases, musculoskeletal disorders, metabolic disorder, immune system dysfunction, osteoarthritis, type 2 diabetes, and age- related hearing loss. The biological fluid sample can be a whole blood, plasma, or serum sample. The elevated level of secreted PD-L2 can be as compared to a reference level present in controls known not to have the senescence-related disease or condition. The identifying can include using an anti-PD-L2 antibody to detect the elevated level of the secreted PD-L2 polypeptide in the sample. The treatment can include an anti-PD-L2 agent, a senolytic agent, an anti-tumor necrosis factor alpha (TNFα) agent, an NF-κB inhibitor, a matrix metalloprotease (MMP) inhibitor, a gamma secretase inhibitor, or any combination thereof. In another aspect, this document features methods for treating a mammal having a senescence-related disease or condition, where the methods include, or consist essentially of, administering, to a mammal identified as having a biological fluid sample with an elevated level of secreted PD-L2, a treatment for the senescence-related disease or condition. The mammal can be a human. The senescence-related disease or condition can be a senescence-related cancer (e.g., a melanoma, a pancreatic adenocarcinoma, an osteosarcoma, a squamous cell carcinoma, a breast cancer, or a head and neck squamous cell carcinoma). The senescence-related disease or condition can be selected from the group consisting of cardiovascular diseases, neurodegenerative diseases, pulmonary diseases, chronic inflammatory diseases, liver diseases, kidney diseases, eye diseases, skin diseases, vascular diseases, musculoskeletal disorders, metabolic disorder, immune system dysfunction, osteoarthritis, type 2 diabetes, and age-related hearing loss. The biological fluid sample can be a whole blood, plasma, or serum sample. The elevated level of secreted PD-L2 can be as compared to a reference level present in controls known not to have the cancer. The mammal can have been identified as having an elevated level of PD-L2 polypeptide in the biological fluid sample by using an anti-PD- L2 antibody to detect the elevated level of the secreted PD-L2 polypeptide. The treatment can include an anti-PD-L2 agent, a senolytic agent, an anti-TNFα agent, an NF-κB inhibitor, a MMP inhibitor, a gamma secretase inhibitor, or any combination thereof. Attorney Docket No.07039-2219WO1 2023-151 In another aspect, this document features methods for assessing the efficacy of a treatment in a mammal having a senescence-related disease or condition. The methods can include, or consist essentially of, determining a first level of PD-L2 in a first biological sample obtained from the mammal prior to administration of the treatment; administering the treatment to the mammal; determining a second level of PD-L2 in a second biological sample obtained from the mammal after administration of the treatment; and when the second level of PD-L2 is lower than the first level of PD-L2, determining that the treatment is effective, or when the second level of PD-L2 is not lower than the first level of PD-L2, determining that the treatment is not effective. The mammal can be a human. The senescence-related disease or condition can be a senescence-related cancer (e.g., a melanoma, a pancreatic adenocarcinoma, an osteosarcoma, a squamous cell carcinoma, a breast cancer, or a head and neck squamous cell carcinoma). The senescence-related disease or condition can be selected from the group consisting of cardiovascular diseases, neurodegenerative diseases, pulmonary diseases, chronic inflammatory diseases, liver diseases, kidney diseases, eye diseases, skin diseases, vascular diseases, musculoskeletal disorders, metabolic disorder, immune system dysfunction, osteoarthritis, type 2 diabetes, and age-related hearing loss. The first and second biological samples can be biological fluid samples, and the PD-L2 can be a secreted PD-L2 polypeptide. The first and second biological fluid samples can be whole blood, plasma, or serum samples. The determining can include detecting a level of secreted PD-L2 polypeptide in the first and second biological fluid samples. The elevated level of PD-L2 can be as compared to a reference level present in controls known not to have the senescence-related disease or condition. The treatment can include an anti-PD- L2 agent, a senolytic agent, an anti-TNFα agent, an NF-κB inhibitor, a MMP inhibitor, a gamma secretase inhibitor, or any combination thereof. In still another aspect, this document features methods for treating a senescence- related disease or condition in a mammal, where the methods include, or consist essentially of, administering, to a mammal having a senescent-related disease or condition and identified as having a biological sample containing an elevated level of PD-L2, (a) an anti-TNFα therapy, an NF-κB inhibitor, or an anti-TNFα and an NF-κB Attorney Docket No.07039-2219WO1 2023-151 inhibitor, and (b) an anti-PD-L2 agent. The mammal can be a human. The senescence- related disease or condition can be a senescence-related cancer (e.g., a melanoma, a pancreatic adenocarcinoma, an osteosarcoma, a squamous cell carcinoma, a breast cancer, or a head and neck squamous cell carcinoma). The senescence-related disease or condition can be selected from the group consisting of cardiovascular diseases, neurodegenerative diseases, pulmonary diseases, chronic inflammatory diseases, liver diseases, kidney diseases, eye diseases, skin diseases, vascular diseases, musculoskeletal disorders, metabolic disorder, immune system dysfunction, osteoarthritis, type 2 diabetes, and age-related hearing loss. The biological sample can be a biological fluid sample, and the PD-L2 can be a secreted PD-L2 polypeptide. The biological fluid sample can be a whole blood, plasma, or serum sample. The elevated level of PD-L2 can be as compared to a reference level present in controls known not to have the senescence-related disease or condition. The method can include administering the anti-TNFα therapy. The anti- TNFα therapy can be selected from the group consisting of etanercept, infliximab, adalimumab, certolizumab pegol, and golimumab. The method can include administering the NF-κB inhibitor. The NF-κB inhibitor can be selected from the group consisting of bortezomib, curcumin, resveratrol, Bay 11-7082, TPCA-1, parthenolide, wedelolactone, celastrol, tanshinone IIA, and thymoquinone. The anti-PD-L2 agent can be an anti-PD-L2 antibody. This document also features methods for treating a senescence-related disease or condition in a mammal, where the methods include, or consist essentially of, administering, to a mammal having a senescence-related disease or condition and identified as having a biological sample containing an elevated level of PD-L2, (a) an MMP inhibitor, a gamma secretase inhibitor, or an MMP inhibitor and a gamma secretase inhibitor, and (b) an anti-PD-L2 agent, a senolytic agent, or an anti-PD-L2 agent and a senolytic agent. The mammal can be a human. The senescence-related disease or condition can be a senescence-related cancer (e.g., a melanoma, a pancreatic adenocarcinoma, an osteosarcoma, a squamous cell carcinoma, a breast cancer, or a head and neck squamous cell carcinoma). The senescence-related disease or condition can be selected from the group consisting of cardiovascular diseases, neurodegenerative Attorney Docket No.07039-2219WO1 2023-151 diseases, pulmonary diseases, chronic inflammatory diseases, liver diseases, kidney diseases, eye diseases, skin diseases, vascular diseases, musculoskeletal disorders, metabolic disorder, immune system dysfunction, osteoarthritis, type 2 diabetes, and age- related hearing loss. The biological sample can be a biological fluid sample, and the PD- L2 can be a secreted PD-L2 polypeptide. The biological fluid sample can be a whole blood, plasma, or serum sample. The elevated level of PD-L2 can be as compared to a reference level present in controls known not to have the senescence-related disease or condition. The method can include administering the MMP inhibitor. The MMP inhibitor can be selected from the group consisting of marimastat (BB-2516), batimastat (BB-94), doxycycline, GM6001 (ilomastat), tetracyclines, collagen peptide-derived inhibitors, and tissue inhibitors of metalloproteinases (TIMPs). The method can include administering the gamma secretase inhibitor. The gamma secretase inhibitor can be selected from the group consisting of semagacestat (LY450139), avagacestat (BMS-708163), RO4929097, MK-0752 (dibenzazepine), LY-411,575, and E2012 (ELND006). The method can include administering the anti-PD-L2 agent. The anti-PD-L2 agent can be an anti-PD-L2 antibody. The method can include administering the senolytic agent. The senolytic agent can be selected from the group consisting of dasatinib, quercetin, navitoclax, A1331852, A1155463, fisetin, luteolin, geldanamycin, tanespimycin, alvespimycin, piperlongumine, panobinostat, FOX04-related peptides, nutlin3a, ruxolitinib, metformin, rapamycin, JAK1 / 2 inhibitors, NF-κB inhibitors, p38 inhibitors, IL-6 inhibitors, and STAT3 inhibitors. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although methods and materials similar or equivalent to those described herein can be used to practice the invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting. Attorney Docket No.07039-2219WO1 2023-151 The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims. DESCRIPTION OF DRAWINGS FIGS.1A-1B show that PD-L2 is upregulated in a human melanoma cell line upon induction of cellular senescence or upon treatment with TNFα, but that the upregulation after induction of senescence is reduced by a κB kinase (IKK) inhibitor. FIG.1A is a pair of graphs plotting PD-L1 and PD-L2 mRNA expression in SK-MEL-28 cells treated with doxorubicin and then with the IKK inhibitor BAY 11-7082 (3 mM, 24 hours). FIG.1B is a graph plotting PD-L1 and PD-L2 mRNA expression in SK-MEL-28 cells treated with TNFα (100 ng / mL, 3 days. MFI = median fluorescence intensity. T- tests or 1-way ANOVA with Tukey post-test were applied. For all experiments in culture, senescence was induced with 200 nM doxorubicin for 48 hours, 5 mM palbociclib for 7 days, or 12 mU bleomycin for 48 hours. Senescence was evaluated at day 7. FIGS.2A-2B in a human pancreatic cancer cell line upon induction of cellular senescence or upon treatment with TNFα, but that the upregulation after induction of senescence is reduced by an IKK inhibitor. FIG.2A is a pair of graphs plotting PD-L1 and PD-L2 mRNA expression in panc1cells treated with doxorubicin and the IKK inhibitor BAY 11-7082 (3 mM, 24 hours). FIG.2B is a graph plotting PD-L1 and PD-L2 mRNA expression in panc1 cells treated with TNFα (100 ng / mL, 3 days). T tests or 1- way ANOVA with Tukey post-test were applied. For all experiments in culture, senescence was induced with 200 nM doxorubicin for 48 hours, 5 mM palbociclib for 7 days, or 12 mU 1146 bleomycin for 48 hours. Senescence was evaluated at day 7. FIGS.3A-3G show that PD-L2 is upregulated by senescent cells. FIG.3A is a series of graphs plotting mRNA levels of PD-L2, PD-L1, p16, and p21 in human preadipocytes, 2 months after the cells were rendered senescent by 20Gy X-ray irradiation. FIG.3B is a pair of graphs plotting mRNA levels of PD-L2 and PD-L1 in human preadipocytes, 14 days after the cells were rendered senescent by doxorubicin. Attorney Docket No.07039-2219WO1 2023-151 FIG.3C includes graphs plotting mRNA levels of PD-L2, PD-L1, and p16 in human preadipocytes rendered senescent by serial passaging for 18 passages. FIG.3D is a pair of graphs plotting PD-L2 and PD-L1 mRNA levels in human umbilical vein endothelial cells (HUVEC), 14 days after the cells were rendered senescent by doxorubicin or irradiation. FIG.3E is a graph plotting PD-L2 and PD-L1 mRNA levels in human renal glomerular endothelial cells, 14 days after they were rendered senescent by doxorubicin or irradiation. FIG.3F is a graph plotting PD-L2 expression on the cell membrane of HUVEC WT and CRISPR generated PD-L2KO cells, 14 days after the cells were rendered senescent by doxorubicin or irradiation. FIG.3G includes graphs plotting PD- L2 mRNA levels in MDA-MB-231, MDA-468, and HS-578 cells, 7 days after they were rendered senescent by doxorubicin. FIGS.4A-4D show that senescent cells secrete PD-L2, and that secretion of PD- L2 is regulated via proteolytic cleavage. FIG.4A is a pair of graphs plotting secreted PD- L2 and PD-L1 levels in conditioned media collected from passage 9 and passage 18 human preadipocytes that were rendered senescent by serial passaging. FIG.4B is a pair of graphs plotting the level of secreted PD-L2 in media from HUVEC WT and CRISPR generated PD-L2KO cells. FIG.4C is a graph plotting secreted PD-L2 levels in conditioned media collected from HUVEC induced to senescence by irradiation after treatment with vehicle, MMP inhibitor, proteinase inhibitor, or gamma secretase inhibitor. FIG.4D is a graph plotting secreted PD-L2 levels in conditioned media collected from IMR90 and MDA-MB-231 cells, 7 days (MDA-MB-231) or 3 weeks (IMR90) after cells were rendered senescent by doxorubicin. FIGS.5A-5F show that PD-L2 is regulated through the NF-κB pathway. FIG.5A is a pair of graphs plotting PD-L2 and PD-L1 mRNA levels in HUVEC that were treated with doxorubicin and then incubated with media containing either vehicle or an IKK inhibitor. FIG.5B is a pair of graphs plotting PD-L2 and PD-L1 mRNA levels in SK- Mel28 cells that were treated with doxorubicin and then incubated with media containing either vehicle or IKK inhibitor. FIG.5C is a pair of graphs plotting PD-L2 and PD-L1 mRNA levels in Panc1 cells that were treated with doxorubicin and then incubated with media containing either vehicle or IKK inhibitor. FIG.5D is a pair of graphs plotting Attorney Docket No.07039-2219WO1 2023-151 PD-L2 and PD-L1 mRNA levels in HUVEC that were treated with recombinant TNFα and then incubated in media containing an IKK inhibitor. FIG.5E is a pair of graphs plotting PD-L2 and PD-L1 mRNA levels in SK-Mel28 cells that were treated with recombinant TNFα. FIG.5F is a pair of graphs plotting PD-L2 and PD-L1 mRNA levels in Panc1 cells that were treated with recombinant TNFα. FIGS.6A-6C show that PD-L2 is regulated by the miR-17-92 cluster. FIG.6A includes graphs plotting expression levels of miRNA-20a, miRNA-106a and miRNA- 106b in HUVEC, 14 days after the cells rendered senescent using doxorubicin. FIG.6B is a series of graphs plotting expression of PD-L2, PD-L1, p21, p16, miRNA-20a, miRNA-106a and miRNA-106b in the liver of 5-month-old and 27-month-old male mice. FIG.6C includes graphs plotting PD-L2, PD-L1, p21, and p16 expression in HUVEC that were rendered senescent using doxorubicin, incubated for 12 days, and then transfected with miRNA-20a, miRNA-106a, or miRNA-106b mimics. FIG.7 shows increased levels of sPD-L2 in senescent associated pathologies. FIG.7 is a graph plotting secreted PD-L2 and PD-L1 levels in plasma samples from healthy and obese human patients. FIGS.8A-8C show that senolytics target PD-L2 high expressing senescent cells. FIG.8A is a pair of graphs plotting PD-L2 and PD-L1 mRNA levels in human preadipocytes after they were rendered senescent by irradiation incubated for 1 month, and then treated with vehicle or the senolytic combination Dasatinib plus Quercetin (D+Q). FIG.8B is a pair of graphs plotting PD-L2 and PD-L1 mRNA levels in human adipose tissue explants that were incubated with D+Q or vehicle. FIG.8C is a pair of graphs plotting secreted PD-L2 and PD-L1 in plasma samples obtained from idiopathic pulmonary fibrosis (IPF) patients before and after treatment with senolytics (D+Q). FIGS.9A-9B show that PD-L2 is increased in senescent associated pathologies. FIG.9A is a graph plotting the percentage of PD-L2 positive area in adipose tissue of young and old human subjects. FIG.9B includes representative images of IHC for PD- L2 in adipose tissue from young and old subjects. FIG.10 is a graph plotting a survival curve for aged male and female PD-L2 WT and PD-L2 KO mice. Attorney Docket No.07039-2219WO1 2023-151 FIGS.11A-11D show that PD-L2KO mice display improved metabolic health. FIG.11A is a graph plotting the results of a glucose tolerance test (GTT) in male 24- month-old PD-L2WT and PD-L2KO mice. FIG.11B is a graph plotting the area under the curve for the GTT study. FIG.11C is a graph plotting the results of an insulin tolerance test (ITT) in male 24-month-old PD-L2WT and PD-L2KO mice. FIG.11D is a graph plotting the area over the curve for the ITT study. FIGS.12A-12B show that anti-PD-L2 targets p16 high expressing cells in human explant cultures. FIG.12A is a graph plotting the level of p16 mRNA expression in adipose tissue explants from healthy human subjects, 24 hours after explants were harvested and incubated with IgG isotype control antibodies or anti-PD-L2. FIG.12B is a graph plotting the level of p16 mRNA expression in adipose tissue explants from obese human subjects, 24 hours after explants were harvested and incubated with IgG isotype control antibodies or anti-PD-L2. FIG.13 shows that old PD-L2-KO mice exhibit reduced senescent cell accumulation. FIG.13 includes a series of graphs plotting the level of PD-L2, p16, p21, OAS2, TNFα, MMP9, CCL5, and OAS3 in 26-month-old male mice. FIG.14 shows that soluble PD-L2 levels are increased in plasma samples from old human subjects as compared to young human subjects. FIG.14 includes graphs plotting levels of sPD-L2, sPD-L1, MMP1, MMP2, MMP3, MMP7, MMP8, MMP9, MMP10, TNFα, TNFR1, and TNFR2 in plasma samples from young and old human patients. FIGS.15A-15J and FIGS.16A-16H show that primary senescent cells have upregulated PD-L2 through NF-κB. FIG.15A includes a series of graphs plotting relative expression levels of senescence and SASP markers in control and irradiation-induced senescent human preadipocytes, assayed by RT-qPCR after 2 months (n=6 ±SD). FIG.15B includes a pair of graphs plotting relative expression levels of p16INK4Aand p21CIP1in replication- induced senescent human preadipocytes by serial passaging (n=4 ±SD). FIG.15C includes representative images (of n=2) showing SAβG of control and irradiation- or doxorubicin-induced senescent human kidney endothelial cells (HRGEC) cells assayed Attorney Docket No.07039-2219WO1 2023-151 after 14 days. FIG.15D includes a pair of graphs plotting relative expression of p16INK4Aand p21CIP1in control and irradiation- or doxorubicin-induced senescent HUVECs, assayed after 14 days (n=4 ±SD). FIG.15E is a schematic depicting the PD-L2 gene in CRISPR-Cas9 engineered HUVEC-PD-L2KO cells. FIG.15F includes a pair of representative images (of n=2) showing HUVEC-NF-κB-GFP reporter cells treated with DMSO or TNF-α, assayed at day 3. Scale bar = 400 μm. FIG.15G includes graphs plotting relative expression of PD-L2, PD-L1, and CCL5 in pre-senescent control HUVECs and in pre-senescent HUVECS treated with doxorubicin without or with IκKi, assayed at day 3 (n=3, ±SD). FIG.15H includes a pair of graphs plotting PD-L2 or PD- L1 expression in control and IFN-γ treated HUVECs (n=4, ±SD). For statistical analyses, unpaired two-sided Welch’s t-tests were performed for FIGS.15A and 15H. FIG.15I shows RT-qPCR-determined levels of senescence and SASP markers in control and irradiation-induced senescent HUVECs and HUVEC-PD-L2KO cells assayed after 10 days (n=3, ±SD). FIG.15J includes representative images showing SAβG of control and either irradiation- or doxorubicin-induced senescent HUVEC and HUVEC-PD-L2KO cells assayed after 14 days. One-way ANOVA was performed for FIGS.15B, 15D, and 15G. P values are exact. FIGS.16A-16H are graphs plotting PD-L2 and PD-L1 expression in: control and irradiation-induced senescent human preadipocytes assayed after 2 months (FIG.16A; n=6, ±SD), control and doxorubicin-induced senescent human preadipocytes assayed after 14 days (FIG.16B; n=4, ±SD), replication-induced senescent human preadipocytes by serial passaging (FIG.16C; n=4, ±SD), control and irradiation- or doxorubicin- induced senescent human kidney endothelial cells (HRGEC) assayed after 14 days (FIG. 16D; n=4, ±SD), and control and irradiation- or doxorubicin-induced senescent HUVECs assayed after 14 days (FIG.16E; n=4, ±SD). FIG.16F is a graph plotting PD-L2 expression as determined by flow cytometry in HUVEC WT control, CRISPR-Cas9- engineered PD-L2 knockout HUVEC, and irradiation- or doxorubicin-induced senescent HUVEC assayed after 14 days (n=3, ±SD). FIG.16G is a graph plotting PD-L2, PD-L1, and CCL5 expression in control, TNF-α treated, and TNF-α + IκKi treated HUVECs (n=3, ±SD). FIG.16H is a graph plotting PD-L2, PD-L1, and CCL5 expression in Attorney Docket No.07039-2219WO1 2023-151 control and irradiation-induced senescent HUVECs treated without or with IκKi and assayed at day 10 (n=3, ±SD). For statistical analyses, unpaired two-sided Welch’s t-tests were performed for FIGS.16A and 16B. One-way ANOVA was performed for FIGS. 16C-16H. P values are exact. FIGS.17A-17G and FIGS.18A-18G show that senescent cells release PD-L2 and senolytics target PD-L2 highly expressing cells. FIG.17A includes a pair of graphs plotting relative expression levels of MMP2 and MMP9 in doxorubicin-induced senescent HUVEC, assayed after 14 days (n=3, ±SD). FIG.17B is a graph plotting sPD-L2 levels in conditioned media of control and irradiation-induced senescent HUVECs treated with vehicle or MMPi and assayed after 7 days (n=4, ±SD). FIG.17C includes a pair of graphs plotting plasma levels of sPD-L2 (n=20, ±SEM) and sPD-L1 (n=8,4; ±SEM) in obese (BMI: 43.2±8.0 kg / m2) and leaner (BMI: 27.2±3.2 kg / m2) subjects. FIG.17D includes a pair of graphs plotting plasma levels of sPD-L2 (n=29,50) and sPD-L1 (n=30,50) in younger (27.1±4.0 years) and older (71.5±4.4 years) subjects (±SEM). FIG.17E includes a pair of graphs plotting PD-L2 and PD-L1 mRNA expression in human adipose tissue explants treated with vehicle or in the surviving fraction of explants post D+Q treatment, assayed after one month (n=6). FIG.17F includes a pair of graphs plotting relative expression of PD-L2 and PD-L1 mRNA in vehicle or D+Q treated human adipose tissue explants (n=6). FIG.17G includes graphs plotting plasma levels of sPD-L2 (n=21) and sPD-L1 (n=5) before and after D+Q treatment in IPF patients, and plasma levels of sPD-L2 (n=6) in observational controls (1stand 2ndvisit). For statistical analyses, unpaired two-sided Welch’s t-test was performed for FIGS.17A, 17C, and 17D. One-way ANOVA was performed for FIG. 17B. Paired two-sided Welch’s t-tests were performed for FIGS.17E-17G. P values are exact. FIG.18A is a graph plotting relative expression levels of MMP13 in control or doxorubicin-induced senescent HUVECs assayed after 14 days (n=3). FIG.18B includes graphs plotting relative expression levels of MMP2, MMP9, and MMP13 in irradiation- induced senescent human preadipocytes assayed after 2 months (n=4, ±SD). FIG.18C includes a pair of graphs plotting sPD-L2 and sPD-L1 levels in conditioned media Attorney Docket No.07039-2219WO1 2023-151 collected from HUVEC WT control or CRISPR-Cas9-engineered PD-L2 knockout cells (n=3, ±SD). FIG.18D includes a pair of graphs plotting sPD-L2 and sPD-L1 levels in conditioned media collected from replication-induced senescent human preadipocytes (n=5). FIG.18E is a graph plotting sPD-L1 levels in conditioned media from control and vehicle or MMPi treated, irradiation-induced senescent HUVECs assayed after 7 days (n=4). FIG.18F is a graph plotting sPD-L2 (n=30,50) plasma levels from younger (27.1±4.0 years) and older (71.5±4.4 years) subjects (±SEM, including a statistically significant outlier). FIG.18G is a graph plotting plasma sPD-L1 levels in observational controls (1stand 2ndvisit). For statistical analyses, unpaired two-sided Welch’s t-tests were performed for FIG.18B. Paired two-sided Welch’s t-tests were performed for FIG. 18D. P values are exact. FIGS.19A-19E and 20A-20F show that PD-L2 is upregulated with aging and that PD-L2KO mice have reduced senescent cell burden. FIG.19A includes survival curves for male and female PD-L2WT and PD-L2KO mice up to 26 months of age. FIGS.19B and 19C include graphs plotting pathological scores assessing disease burden (FIG.19B) and tumor burden (FIG.19C) in male (n=6,6,13,13; ±SEM) and female (n=5,5,10,9; ±SEM) young (4-month) and old (26- month) WT and PD-L2KO mice. FIGS.19D and 19E include representative images of H&E staining in liver (FIG.19D) and adipose tissue (FIG.19E) from male and female young (4-month) and old (26-month) WT and PD-L2KO mice. For statistical analyses, one-way ANOVA was performed for FIGS.19B and 19C. Log-rank (Mantel Cox) test was performed for FIG.19A. P values are exact. FIGS.20A and 20B includes graphs plotting expression levels of PD-L2 and PD- L1 expression in liver, skeletal muscle, and adipose tissue of young (4-month) and old (26-month) male (FIG.20A; n=6,12; ±SEM) or female (FIG.20B; n=5,7; ±SEM) PD- L2WT mice. FIG.20C includes a graph (top) providing quantification and representative images (bottom) of PD-L2 immunohistochemistry staining of human adipose tissue from younger (28.1±2.8 years) and older (73.0±4.6 years) subjects (n=10,8; ±SEM). Scale bar 100 μm. FIG.20D includes graphs plotting expression levels of p16Ink4a, p21Cip1, Tnf-α, Ccl5, Mmp9, Oas2, and Oas3 in livers from young (4-month) and old (26-month) PD- Attorney Docket No.07039-2219WO1 2023-151 L2WT and PD-L2KO male mice (n=6,6,12,12; ±SEM). FIG.20E includes graphs plotting expression levels of p16Ink4a, p21Cip1, Ccl2, Gdf15, and Mmp3 in skeletal muscle from young (4-month) and old (26-month) WT and PD-L2KO female mice (n=5,5,7,6; ±SEM). FIG.20F includes graphs plotting histopathological scores assessing inflammatory status in male (n=6,6,13,13; ±SEM) and female (n=5,5,10,9; ±SEM) young (4-month) and old (26-month) PD-L2WT and PD-L2KO mice. For statistical analyses, unpaired two-sided Welch’s t-tests were performed for FIGS.20A-20C. One-way ANOVA was performed for FIGS.20D-20F. P values are exact. FIGS.21A-21L and 22A-22G show that blocking PD-L2 alleviates age-related dysfunction & accelerates senescent cell clearance. FIG.21A includes graphs plotting the results of GTT in 24-month-old WT and PD-L2KO male mice and corresponding areas under the curve (n=15, ±SEM). FIG.21B is a graph plotting fasting glucose levels in old WT and PD-L2KO male mice (n=15, ±SEM). FIG.21C includes graphs plotting the results of ITT in 24-month-old WT and PD-L2KO male mice (n=15, ±SEM). FIG.21D includes graphs plotting the results of GTT in young (4-month) WT and PD-L2KO male mice (n=6, ±SEM). FIG.21E is a graph plotting fasting glucose levels in young (4-month) WT and PD-L2KO male mice (n=6, ±SEM). FIG.21F includes graphs plotting the results of ITT in young (4-month) WT and PD-L2KO male mice (n=6, ±SEM). FIG.21G is a schematic illustrating an experimental setup for anti-PD-L2 therapy. FIG.21H includes graphs plotting the results of ITT in 22-month-old WT male mice before and after treatment with IgG or anti-PD-L2 therapy (n=9,9,8,8; ±SEM). FIG.21I is a graph plotting grip strength in 22 month-old WT and PD-L2KO female mice (n=16,15; ±SEM). FIG.21J is a schematic illustrating an experimental setup for autologous transplantation. FIGS.21K and 21L show bioluminescence (FIG.21L) and quantification (FIG.21K) of control and senescent WT and PD-L2KO cells (n=8,7,8,7; ±SEM). For statistical analyses, unpaired two-sided Welch’s t-tests were performed for FIGS.21B, 21C, 21E, 21F, and 21I. One-way ANOVA was performed for FIGS.21H and 21K. P values are exact. FIG.22A includes graphs plotting the results of GTT in 24-month-old WT and PD-L2KO female mice (n=10,9; ±SEM). FIG.22B is a graph plotting fasting glucose Attorney Docket No.07039-2219WO1 2023-151 levels in 24-month-old WT and PD-L2KO female mice (n=10,9; ±SEM). FIG.22C includes graphs plotting the results of ITT in 24-month-old WT and PD-L2KO female mice (n=10,9; ±SEM). FIG.22D is a graph plotting grip strength in 22-month-old WT and PD-L2KO male mice (n=13,17; ±SEM). FIG.22E is a pair of graphs plotting expression levels of PD-L2 and PD-L1 in control and doxorubicin-induced senescent mouse ear fibroblasts assayed after 10 days (n=4, ±SD). FIG.22F is a schematic illustrating CRISPR-Cas9 engineering of PD-L2 in mouse ear fibroblasts, showing WT (SEQ ID NO:16) and KO (SEQ ID NO:17) sequences. FIG.22G includes a pair of graphs plotting expression levels of p16Ink4aand p21Cip1in proliferating and senescent WT, PD-L2KO mouse ear fibroblasts assayed after 10 days (n=8,7,8,7; ±SD). For statistical analyses, unpaired two-sided Welch’s t-tests were performed for FIGS.22A- 22E. One-way ANOVA was performed for FIG.22G. P values are exact. DETAILED DESCRIPTION This document provides methods and materials for assessing and / or treating mammals (e.g., humans) having senescence-related diseases or disorders. In some cases, the methods and materials provided herein can be used to determine if a mammal (e.g., a human) has, or is likely to have, a senescence-related cancer (e.g., a melanoma, a pancreatic adenocarcinoma, an osteosarcoma, a squamous cell carcinoma, a breast cancer, or a head and neck squamous cell carcinoma). In some cases, the methods and materials provided herein can be used to determine if a mammal (e.g., a human) has, or is likely to have, another senescence-related disease or condition. Non-limiting examples of such diseases and conditions include aging, as senescent cells accumulate naturally with age; cardiovascular diseases, as senescent cells can accumulate in blood vessels and contribute to atherosclerosis, hypertension, and other cardiovascular conditions; neurodegenerative diseases, as senescent cells and inflammation can play a role in neurodegenerative conditions (e.g., Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease); osteoarthritis, as senescent cells can accumulate in joint tissues and contribute to the degeneration of cartilage; pulmonary diseases, as senescent cells in the lungs can contribute to chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis; Attorney Docket No.07039-2219WO1 2023-151 liver diseases, as senescence and senescent cell accumulation can contribute to liver fibrosis, cirrhosis, and hepatocellular carcinoma; kidney diseases, as senescent cells can accumulate in the kidneys and contribute to kidney aging and age-related renal dysfunction; diabetes, as senescence can affect pancreatic beta cells, leading to impaired insulin secretion and the development of type 2 diabetes; eye diseases, as senescent cells and inflammation can contribute to age-related macular degeneration (AMD) and other age-related eye conditions; skin diseases, as senescent cells can accumulate in the skin and contribute to age-related changes such as wrinkles and loss of elasticity; musculoskeletal disorders, as senescent cells can accumulate in muscles and contribute to age-related muscle loss (sarcopenia) and weakness; metabolic disorders, as senescent cells can impact metabolic function and contribute to conditions such as metabolic syndrome and obesity; immune system dysfunction, as senescent cells can accumulate in the immune system and contribute to immunosenescence, impairing immune function and increasing susceptibility to infections and diseases; chronic inflammatory diseases, as senescent cells can contribute to chronic inflammation associated with conditions like rheumatoid arthritis and inflammatory bowel disease; age-related hearing loss, as senescent cells in the inner ear can contribute to age-related hearing loss (presbycusis); and vascular diseases, as senescent cells can accumulate in blood vessels and contribute to vascular aging and diseases such as peripheral artery disease. In some cases, a biological sample (e.g., biological fluid sample) obtained from a mammal can be assessed to determine if the mammal has, or is likely to have, a senescence-related disease or condition e.g., a senescence-related cancer, cardiovascular disease, neurodegenerative disease, pulmonary disease, chronic inflammatory disease, liver disease, kidney disease, eye disease, skin disease, vascular disease, musculoskeletal disorder, or metabolic disorder, or a senescence-related condition such as immune system dysfunction, osteoarthritis, type 2 diabetes, or age-related hearing loss), based at least in part on the presence of an elevated level of PD-L2 (e.g., a PD-L2 polypeptide, such as a secreted PD-L2 polypeptide) in the sample. For example, a plasma sample obtained from a mammal can be assessed to determine if the mammal has, or is likely to have, a senescence-related disease or condition based, at least in part on, whether the sample Attorney Docket No.07039-2219WO1 2023-151 contains an elevated level of PD-L2 as compared to controls (e.g., controls known to not have the senescence-related disease or condition). The term “elevated level” as used herein with respect to a level of PD-L2 (e.g., a PD-L2 polypeptide, such as a secreted PD-L2 polypeptide) in a biological sample from a mammal refers to any level that is higher than a reference level of PD-L2. For example, an elevated level of PD-L2 can be at least 5 percent (e.g., at least 10, at least 20, at least 25, at least 30, at least 40, at least 50, at least 60, at least 70, at least 75, at least 80, at least 90, or at least 100 percent) higher than a reference level of PD-L2. The term “reference level” as used herein with respect to a level of PD-L2 refers to the level of a PD-L2 polypeptide (e.g., a secreted PD-L2 polypeptide) or expressed PD-L2 nucleic acid (e.g., PD-L2 mRNA) typically observed in a control sample. Control samples are samples obtained from mammals (e.g., humans) that do not have a senescence-related disease or condition (e.g., a senescence-related cancer, cardiovascular disease, neurodegenerative disease, pulmonary disease, chronic inflammatory disease, liver disease, kidney disease, eye disease, skin disease, vascular disease, musculoskeletal disorder, or metabolic disorder, or a senescence-related condition such as immune system dysfunction, osteoarthritis, type 2 diabetes, or age-related hearing loss). Any appropriate biological sample can be assessed to detect the presence, absence, or level of PD-L2. In some cases, a biological sample can be a sample of a biological fluid. Examples of biological fluid samples that can be assessed as described herein include, without limitation, blood samples (e.g., whole blood, serum, or plasma samples), urine, cerebrospinal fluid, and saliva. For example, a plasma sample can be assessed to detect the presence, absence, or level of a secreted PD-L2 polypeptide. In some cases, a biological sample can be a tissue sample. For example, a biopsy (e.g., a skin biopsy, liver biopsy, spleen biopsy, kidney biopsy, heart biopsy, or lung biopsy) or a tumor sample can be obtained from a mammal and used to determine the presence, absence, or level of a PD-L2 polypeptide or expressed PD-L2 nucleic acid (e.g., a PD-L2 mRNA). Any appropriate method can be used to identify a mammal as having a biological sample with an elevated level of PD-L2 (e.g., a PD-L2 polypeptide such as a secreted Attorney Docket No.07039-2219WO1 2023-151 PD-L2 polypeptide, or an expressed PD-L2 nucleic acid such as a PD-L2 mRNA). For example, a level of a PD-L2 polypeptide can be determined using immunoassays (e.g., immunohistochemical (IHC) methods and western blotting techniques), mass spectrometry techniques (e.g., proteomics-based mass spectrometry assays or targeted quantification-based mass spectrometry assays), enzyme-linked immunosorbent assays (ELISA), and flow cytometry. When an immunoassay is used to determine the level of a PD-L2 polypeptide in a sample, the immunoassay can use any appropriate antibody. Examples of antibodies that can be used in an immunoassay to determine the level of a PD-L2 polypeptide in a sample include, without limitation, a clone MIH18 anti-PD-L2 antibody, a clone TY25 anti-PD-L2 antibody, a clone 122 anti-PD-L2 antibody, and a clone MIH18.2 anti-PD-L2 antibody (all commercially available from ThermoFisher Scientific). In some cases, the level of mRNA encoding a PD-L2 polypeptide can be measured to indicate the level of a PD-L2 polypeptide within a sample obtained from a mammal being assessed. For example, a sample containing cells can be obtained from a mammal, and the level of mRNA encoding PD-L2 polypeptide can be measured to determine if the level of PD-L2 polypeptide within the sample is elevated compared to a reference level of PD-L2. Any appropriate method can be used to measure the level of mRNA encoding a PD-L2 polypeptide within a sample. For example, polymerase chain reaction (PCR)-based techniques such as quantitative reverse transcription (RT)-PCR (qRT-PCR) techniques, and RNA-fluorescence in situ hybridization (FISH) can be used to determine the presence, absence, or level of mRNA encoding a PD-L2 polypeptide in the sample. A representative amino acid sequence for a full length human PD-L2 polypeptide is set forth in SEQ ID NO:1, and a representative PD-L2 ectodomain sequence (lacking the intracellular and transmembrane domains) is set forth in SEQ ID NO:2. A representative nucleotide sequence encoding a human PD-L2 polypeptide is set forth in SEQ ID NO:3. MIFLLLMLSLELQLHQIAALFTVTVPKELYIIEHGSNVTLECNFDTGSHVNL GAITASLQKVENDTSPHRERATLLEEQLPLGKASFHIPQVQVRDEGQYQCIIIYGV Attorney Docket No.07039-2219WO1 2023-151 AWDYKYLTLKVKASYRKINTHILKVPETDEVELTCQATGYPLAEVSWPNVSVPA NTSHSRTPEGLYQVTSVLRLKPPPGRNFSCVFWNTHVRELTLASIDLQSQMEPRTH PTWLLHIFIPFCIIAFIFIATVIALRKQLCQKLYSSKDTTKRPVTTTKREVNSAI (SEQ ID NO:1) LFTVTVPKELYIIEHGSNVTLECNFDTGSHVNLGAITASLQKVENDTSPHRE RATLLEEQLPLGKASFHIPQVQVRDEGQYQCIIIYGVAWDYKYLTLKVKASYRKI NTHILKVPETDEVELTCQATGYPLAEVSWPNVSVPANTSHSRTPEGLYQVTSVLRL KPPPGRNFSCVFWNTHVRELTLASIDLQSQMEPRTHPT (SEQ ID NO:2) ACTCTCATGTTACGGCAAACCTTAAGCTGAATGAACAACTTTTCTTCTC TTGAATATATCTTAACGCCAAATTTTGAGTGCTTTTTTGTTACCCATCCTCATATG TCCCAGCTAGAAAGAATCCTGGGTTGGAGCTACTGCATGTTGATTGTTTTGTTT TTCCTTTTGGCTGTTCATTTTGGTGGCTACTATAAGGAAATCTAACACAAACAG CAACTGTTTTTTGTTGTTTACTTTTGCATCTTTACTTGTGGAGCTGTGGCAAGT CCTCATATCAAATACAGAACATGATCTTCCTCCTGCTAATGTTGAGCCTGGAAT TGCAGCTTCACCAGATAGCAGCTTTATTCACAGTGACAGTCCCTAAGGAACTG TACATAATAGAGCATGGCAGCAATGTGACCCTGGAATGCAACTTTGACACTGG AAGTCATGTGAACCTTGGAGCAATAACAGCCAGTTTGCAAAAGGTGGAAAAT GATACATCCCCACACCGTGAAAGAGCCACTTTGCTGGAGGAGCAGCTGCCCCT AGGGAAGGCCTCGTTCCACATACCTCAAGTCCAAGTGAGGGACGAAGGACAG TACCAATGCATAATCATCTATGGGGTCGCCTGGGACTACAAGTACCTGACTCTG AAAGTCAAAGCTTCCTACAGGAAAATAAACACTCACATCCTAAAGGTTCCAGA AACAGATGAGGTAGAGCTCACCTGCCAGGCTACAGGTTATCCTCTGGCAGAAG TATCCTGGCCAAACGTCAGCGTTCCTGCCAACACCAGCCACTCCAGGACCCCT GAAGGCCTCTACCAGGTCACCAGTGTTCTGCGCCTAAAGCCACCCCCTGGCA GAAACTTCAGCTGTGTGTTCTGGAATACTCACGTGAGGGAACTTACTTTGGCC AGCATTGACCTTCAAAGTCAGATGGAACCCAGGACCCATCCAACTTGGCTGCT TCACATTTTCATCCCCTTCTGCATCATTGCTTTCATTTTCATAGCCACAGTGATA GCCCTAAGAAAACAACTCTGTCAAAAGCTGTATTCTTCAAAAGACACAACAA AAAGACCTGTCACCACAACAAAGAGGGAAGTGAACAGTGCTATCTGAACCTG TGGTCTTGGGAGCCAGGGTGACCTGATATGACATCTAAAGAAGCTTCTGGACT Attorney Docket No.07039-2219WO1 2023-151 CTGAACAAGAATTCGGTGGCCTGCAGAGCTTGCCATTTGCACTTTTCAAATGC CTTTGGATGACCCAGCACTTTAATCTGAAACCTGCAACAAGACTAGCCAACAC CTGGCCATGAAACTTGCCCCTTCACTGATCTGGACTCACCTCTGGAGCCTATG GCTTTAAGCAAGCACTACTGCACTTTACAGAATTACCCCACTGGATCCTGGAC CCACAGAATTCCTTCAGGATCCTTCTTGCTGCCAGACTGAAAGCAAAAGGAAT TATTTCCCCTCAAGTTTTCTAAGTGATTTCCAAAAGCAGAGGTGTGTGGAAATT TCCAGTAACAGAAACAGATGGGTTGCCAATAGAGTTATTTTTTATCTATAGCTT CCTCTGGGTACTAGAAGAGGCTATTGAGACTATGAGCTCACAGACAGGGCTTC GCACAAACTCAAATCATAATTGACATGTTTTATGGATTACTGGAATCTTGATAG CATAATGAAGTTGTTCTAATTAACAGAGAGCATTTAAATATACACTAAGTGCAC AAATTGTGGAGTAAAGTCATCAAGCTCTGTTTTTGAGGTCTAAGTCACAAAGC ATTTGTTTTAACCTGTAATGGCACCATGTTTAATGGTGGTTTTTTTTTTGAACTA CATCTTTCCTTTAAAAATTATTGGTTTCTTTTTATTTGTTTTTACCTTAGAAATCA ATTATATACAGTCAAAAATATTTGATATGCTCATACGTTGTATCTGCAGCAATTTC AGATAAGTAGCTAAAATGGCCAAAGCCCCAAACTAAGCCTCCTTTTCTGGCCC TCAATATGACTTTAAATTTGACTTTTCAGTGCCTCAGTTTGCACATCTGTAATAC AGCAATGCTAAGTAGTCAAGGCCTTTGATAATTGGCACTATGGAAATCCTGCA AGATCCCACTACATATGTGTGGAGCAGAAGGGTAACTCGGCTACAGTAACAGC TTAATTTTGTTAAATTTGTTCTTTATACTGGAGCCATGAAGCTCAGAGCATTAGC TGACCCTTGAACTATTCAAATGGGCACATTAGCTAGTATAACAGACTTACATAG GTGGGCCTAAAGCAAGCTCCTTAACTGAGCAAAATTTGGGGCTTATGAGAATG AAAGGGTGTGAAATTGACTAACAGACAAATCATACATCTCAGTTTCTCAATTCT CATGTAAATCAGAGAATGCCTTTAAAGAATAAAACTCAATTGTTATTCTTCAAC GTTCTTTATATATTCTACTTTTGGGTA (SEQ ID NO:3) In some cases, methods and materials provided herein can be used to treat a mammal (e.g., a human) identified as having, or as being likely to have, a senescence- related disease or condition e.g., a senescence-related cancer, cardiovascular disease, neurodegenerative disease, pulmonary disease, chronic inflammatory disease, liver disease, kidney disease, eye disease, skin disease, vascular disease, musculoskeletal disorder, or metabolic disorder, or a senescence-related condition such as immune system Attorney Docket No.07039-2219WO1 2023-151 dysfunction, osteoarthritis, type 2 diabetes, or age-related hearing loss) based, at least in part, on the presence of an elevated level of PD-L2 (e.g., a PD-L2 polypeptide, such as a secreted PD-L2 polypeptide) in a biological sample from the mammal. For example, one or more anti-PD-L2 agents can be administered to a mammal (e.g., a human) to treat a senescence-related disease or condition. For example, one or more anti-PD-L2 agents can be administered to a mammal (e.g., a human) having a senescence-related disease or condition to reduce a level of PD-L2 polypeptide within the mammal. For example, one or more anti-PD-L2 agents can be administered to a mammal (e.g., a human) having a senescence-related disease or condition to reduce a level of PD-L2 mRNA within the mammal. For example, one or more anti-PD-L2 agents can be administered to a mammal (e.g., a human) having a senescence-related disease or condition to reduce a level of PD- L2 activity within the mammal. Examples of anti-PD-L2 agents that can be used in the methods provided herein include, without limitation, anti-PD-L2 antibodies (e.g., a clone MIH18 anti-PD-L2 antibody, a clone TY25 anti-PD-L2 antibody, a clone 122 anti-PD-L2 antibody, or a clone MIH18.2 anti-PD-L2 antibody, all commercially available from ThermoFisher Scientific). The term “reduced level” as used herein with respect to a level of a PD-L2 polypeptide in a mammal refers to any level that is lower than the level of that PD-L2 polypeptide observed in that mammal prior to being treated as described herein (e.g., by administering one or more anti-PD-L2 agents). In some cases, a reduced level of a PD-L2 polypeptide can be a level that is at least 5 percent (e.g., at least 10, at least 15, at least 20, at least 25, at least 35, at least 50, at least 75, or at least 90 percent) lower than the level of that PD-L2 polypeptide prior to being treated as described herein. In some cases, a reduced level of a PD-L2 polypeptide can be a level that is at least 1.5-fold (e.g., about 1.5-fold, about 2-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 5- fold, or more than 5-fold) lower than the level of that PD-L2 polypeptide prior to being treated as described herein. It will be appreciated that levels from comparable samples are used when determining whether or not a particular level is a reduced level. The term “reduced level” as used herein with respect to a level of a PD-L2 mRNA in a mammal refers to any level that is lower than the level of that PD-L2 mRNA Attorney Docket No.07039-2219WO1 2023-151 observed in that mammal prior to being treated as described herein (e.g., by administering one or more anti-PD-L2 agents). In some cases, a reduced level of a PD-L2 mRNA can be a level that is at least 5 percent (e.g., at least 10, at least 15, at least 20, at least 25, at least 35, at least 50, at least 75, or at least 90 percent) lower than the level of that PD-L2 mRNA prior to being treated as described herein. In some cases, a reduced level of a PD- L2 mRNA can be a level that is at least 1.5-fold (e.g., about 1.5-fold, about 2-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 5-fold, or more than 5-fold) lower than the level of that PD-L2 mRNA prior to being treated as described herein. It will be appreciated that levels from comparable samples are used when determining whether or not a particular level is a reduced level. The term “reduced level” as used herein with respect to a level of a PD-L2 activity in a mammal refers to any level that is lower than the level of that PD-L2 activity observed in that mammal prior to being treated as described herein (e.g., by administering one or more anti-PD-L2 agents). In some cases, a reduced level of a PD-L2 activity can be a level that is at least 5 percent (e.g., at least 10, at least 15, at least 20, at least 25, at least 35, at least 50, at least 75, or at least 90 percent) lower than the level of that PD-L2 activity prior to being treated as described herein. In some cases, a reduced level of a PD- L2 activity can be a level that is at least 1.5-fold (e.g., about 1.5-fold, about 2-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 5-fold, or more than 5-fold) lower than the level of that PD-L2 activity prior to being treated as described herein. It will be appreciated that levels from comparable samples are used when determining whether or not a particular level is a reduced level. In some cases, one or more (e.g., one, two, three, four, or more) anti-PD-L2 agents can be used to reduce one or more symptoms of a senescence-related disease or condition e.g., a senescence-related cancer, cardiovascular disease, neurodegenerative disease, pulmonary disease, chronic inflammatory disease, liver disease, kidney disease, eye disease, skin disease, vascular disease, musculoskeletal disorder, or metabolic disorder, or a senescence-related condition such as immune system dysfunction, osteoarthritis, type 2 diabetes, or age-related hearing loss). For example, one or more anti-PD-L2 agents can be administered to a mammal (e.g., a human) in need thereof (e.g., Attorney Docket No.07039-2219WO1 2023-151 a human identified as having a senescence-related disease based, at least in part, on the presence of an elevated level of PD-L2) to reduce one or more symptoms of the senescence-related disease. Examples of symptoms of senescence-related diseases include, without limitation, fatigue; muscle weakness; joint pain and / or stiffness; problems with memory, concentration, and / or cognitive functions; decline in vision and / or hearing; shortness of breath; cardiovascular symptoms such as chest pain, palpitations, shortness of breath, and / or swelling in the legs; frequent infections; skin changes such as dryness, wrinkles, thinning, and increased susceptibility to skin infections; and metabolic disturbances such as weight gain, difficulty losing weight, increased blood sugar levels, high blood pressure, and / or abnormal cholesterol levels. In some cases, one or more anti-PD-L2 agents can be used to reduce one or more symptoms of a senescence-related disease in a mammal by, for example, 10, 20, 30, 40, 50, 60, 70, 80, 90, 95, or more than 95 percent. In some cases, one or more anti-PD-L2 agents can be used to reduce one or more symptoms of a senescence-related disease associated in a mammal having the disease by, for example, at least 1.5-fold (e.g., about 1.5-fold, about 2-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 5-fold, or more than 5-fold). In some cases, one or more (e.g., one, two, three, four, or more) anti-PD-L2 agents can be used to slow the progression of a senescence-related disease or condition e.g., a senescence-related cancer, cardiovascular disease, neurodegenerative disease, pulmonary disease, chronic inflammatory disease, liver disease, kidney disease, eye disease, skin disease, vascular disease, musculoskeletal disorder, or metabolic disorder, or a senescence-related condition such as immune system dysfunction, osteoarthritis, type 2 diabetes, or age-related hearing loss) in a mammal (e.g., a human). For example, one or more anti-PD-L2 agents can be administered to a mammal (e.g., a human) in need thereof (e.g., a human having a senescence-related disease) to slow the progression of the disease in the mammal. In some cases, one or more anti-PD-L2 agents can be effective to slow the progression of a senescence-related disease in a mammal by, for example, 10, 20, 30, 40, 50, 60, 70, 80, 90, 95, or more than 95 percent. In some cases, one or more anti-PD- L2 agents can be used to slow the progression of a senescence-related disease in a Attorney Docket No.07039-2219WO1 2023-151 mammal by, for example, at least 6 months (e.g., at least 6 months, at least 8 months, at least 10 months, at least 1 year, at least 1.5 years, at least 2 years, at least 2.5 years, at least 3 years, at least 4 years, or at least 5 years). In some cases, one or more (e.g., one, two, three, four, or more) anti-PD-L2 agents can be used to increase the survival of a mammal (e.g., a human) having a senescence-related disease or condition (e.g., a senescence-related cancer, cardiovascular disease, neurodegenerative disease, pulmonary disease, chronic inflammatory disease, liver disease, kidney disease, eye disease, skin disease, vascular disease, musculoskeletal disorder, or metabolic disorder, or a senescence-related condition such as immune system dysfunction, osteoarthritis, type 2 diabetes, or age-related hearing loss). For example, a composition containing one or more anti-PD-L2 agents can be administered to a mammal (e.g., a human) in need thereof (e.g., a human having a senescence-related disease or disorder) to increase the survival of the mammal. In some cases, one or more anti-PD-L2 agents can be used to increase the survival of a mammal having a senescence-related disease by, for example, 10, 20, 30, 40, 50, 60, 70, 80, 90, 95, or more than 95 percent. Any appropriate mammal can be assessed and / or treated as described herein (e.g., by administering one or more anti-PD-L2 agents). Examples of mammals that can be assessed and / or treated as described herein include, without limitation, humans, non- human primates (e.g., monkeys), dogs, cats, horses, cows, pigs, sheep, mice, and rats. When treating a mammal (e.g., a human) having a senescence-related disease or condition associated with an elevated level of PD-L2 as described herein, the mammal can have any type of senescence-related disease. For example, the senescence-related disease can be cancer. In some cases, the senescence-related disease can be an age-related disease. In some cases, the senescence-related disease can be a senescence-related cardiovascular disease, neurodegenerative disease, pulmonary disease, chronic inflammatory disease, liver disease, kidney disease, eye disease, skin disease, vascular disease, musculoskeletal disorder, or metabolic disorder, or a senescence-related condition such as immune system dysfunction, osteoarthritis, type 2 diabetes, or age- related hearing loss. Attorney Docket No.07039-2219WO1 2023-151 A mammal (e.g., a human identified as having a senescence-related disease based, at least in part, on an elevated level of PD-L2) can be administered or instructed to self- administer any appropriate one or more (e.g., one, two, three, four, or more) anti-PD-L2 agents. An anti-PD-L2 agent can inhibit PD-L2 polypeptide activity or can inhibit PD-L2 polypeptide expression. Examples of compounds that can inhibit PD-L2 polypeptide activity include, without limitation, antibodies (e.g., neutralizing antibodies) that target (e.g., target and bind to) a PD-L2 polypeptide, and small molecules that target (e.g., target and bind to) to a PD-L2 polypeptide. Examples of compounds that can inhibit PD- L2 polypeptide expression include, without limitation, nucleic acid molecules designed to induce RNA interference of polypeptide expression of a PD-L2 polypeptide (e.g., a siRNA molecule a shRNA molecule), antisense molecules, miRNAs, and nucleic acid molecules designed to induce CRISPR interference (CRISPRi) of PD-L2 polypeptide expression (e.g., a guide RNA (gRNA) molecule complexed with a Cas9 polypeptide such as catalytically dead Cas9 polypeptide (see, e.g., Saifaldeen et al., Cells, 9:2518 (2020) at, for example, Figure 1, Figure 2, and Table 1)). One or more anti-PD-L2 agents can be administered to a mammal (e.g., a human) in need thereof (e.g., a human having a senescence-related disease such as cancer) by any appropriate route (e.g., oral, intranasal, inhalation, transdermal, and parenteral). One or more anti-PD-L2 agents can be administered to a mammal locally or systemically. For example, one or more anti-PD-L2 agents can be administered locally by direct injection (e.g., intratumoral injection) administration to a mammal (e.g., a human). For example, one or more anti-PD-L2 agents can be administered systemically by oral or intravenous administration to a mammal (e.g., a human). One or more anti-PD-L2 agents can be administered to a mammal (e.g., a human) in need thereof (e.g., a human identified as having, or being likely to have, a senescence- related disease based, at least in part, on the presence of an elevated level of PD-L2) in any appropriate amount (e.g., any appropriate dose). An effective amount of one or more anti-PD-L2 agents can be any amount that reduces a level of a PD-L2 polypeptide, an expressed PD-L2 mRNA, or PD-L2 activity within cells of a mammal being treated, without producing significant toxicity to the mammal. In some cases, an effective amount Attorney Docket No.07039-2219WO1 2023-151 of one or more anti-PD-L2 agents can be any amount that reduces one or more symptoms of a senescence-related disease in a mammal being treated, and / or that slows progression of a senescence-related disease in a mammal being treated, and / or that prolongs survival of a mammal being treated. The effective amount can remain constant or can be adjusted as a sliding scale or variable dose depending on the mammal’s response to treatment. Various factors can influence the actual effective amount used for a particular application. For example, the frequency of administration, duration of treatment, use of multiple treatment agents, route of administration, and / or severity of the condition(s) in the mammal being treated may require an increase or decrease in the actual effective amount administered. In some cases, an effective amount of an anti-PD-L2 agent can be from about 0.1 mg / kg to about 10 mg / kg (e.g., about 0.1 to about 0.5 mg / kg, about 0.5 to about 1 mg / kg, about 1 to about 2 mg / kg, about 2 to about 3 mg / kg, about 3 to about 5 mg / kg, about 5 to about 7 mg / kg, or about 7 to about 10 mg / kg). One or more anti-PD-L2 agents can be administered to a mammal (e.g., a human) in need thereof (e.g., a human identified as having, or being likely to have, a senescence- related disease based, at least in part, on the presence of an elevated level of PD-L2) at any appropriate frequency. The frequency of administration can be any frequency that reduces a level of a PD-L2 polypeptide, an expressed PD-L2 mRNA, or PD-L2 activity within cells of a mammal being treated, without producing significant toxicity to the mammal. In some cases, an effective frequency can be any frequency that reduces one or more symptoms of a senescence-related disease in a mammal being treated, and / or that slows progression of a senescence-related disease in a mammal being treated, and / or that prolongs survival of a mammal being treated. For example, the frequency of administration can be from about twice a month to about once a month, from about twice a day to about one every other day, from about once a day to about once a week, from about once a day to about once a month, or from about once a week to about once a month. The frequency of administration can remain constant or can be variable during the duration of treatment. As with the effective amount, various factors can influence the actual frequency of administration used for a particular application. For example, the Attorney Docket No.07039-2219WO1 2023-151 effective amount, duration of treatment, use of multiple treatment agents, and / or route of administration may require an increase or decrease in administration frequency. One or more anti-PD-L2 agents can be administered to a mammal (e.g., a human) in need thereof (e.g., a human identified as having, or being likely to have, a senescence- related disease based, at least in part, on the presence of an elevated level of PD-L2) for any appropriate duration. An effective duration for administering or using one or more anti-PD-L2 agents can be any duration that reduces a level of a PD-L2 polypeptide, an expressed PD-L2 mRNA, or PD-L2 activity within cells of a mammal being treated, without producing significant toxicity to the mammal. In some cases, an effective duration can be any duration that reduces one or more symptoms of a senescence-related disease in a mammal being treated, and / or that slows progression of a senescence-related disease in a mammal being treated, and / or that prolongs survival of a mammal being treated. For example, the effective duration can vary from several days to a lifetime, from several weeks to several months, from several months to several years, or from several years to a lifetime. Multiple factors can influence the actual effective duration used for a particular treatment. For example, an effective duration can vary with the frequency of administration, effective amount, use of multiple treatment agents, and / or route of administration. In some cases, the methods for treating a mammal (e.g., a mammal such as a human identified as having a senescence-related disease based, at least in part, on the presence of an elevated level of PD-L2) as described herein can include administering to the mammal one or more anti-PD-L2 agents as the sole active ingredient(s) to treat the mammal. For example, a composition containing an anti-PD-L2 agent can include the anti-PD-L2 agent as the sole active ingredient in the composition that is effective to treat a mammal (e.g., a mammal having a senescence-related disease). In some cases, the methods for treating a mammal (e.g., a human identified as having a senescence-related disease based, at least in part, on the presence of an elevated level of PD-L2) as described herein (e.g., by administering one or more anti-PD-L2 agents) also can include administering to the mammal one or more (e.g., one, two, three, four, five or more) additional agents / therapies. Attorney Docket No.07039-2219WO1 2023-151 In some cases, a mammal (e.g., a human identified as having a senescence-related disease based, at least in part, on the presence of an elevated level of PD-L2) can be administered (or instructed to self-administer) one or more anti-PD-L2 agents and can be administered (or instructed to self-administer) one or more senolytic agents. A senolytic agent (also referred to as an anti-senescence treatment) is a treatment designed to inhibit or reduce cellular senescence within a mammal. Examples of senolytic agents that can be used in the methods described herein include, without limitation, dasatinib, quercetin, navitoclax, A1331852, A1155463, fisetin, luteolin, geldanamycin, tanespimycin, alvespimycin, piperlongumine, panobinostat, FOX04-related peptides, nutlin3a, ruxolitinib, metformin, rapamycin, JAK1 / 2 inhibitors (e.g., ruxolitinib, AZD 1480), NF- κB inhibitors, p38 inhibitors, IL-6 inhibitors, and STAT3 inhibitors (e.g., LLL12). In cases where one or more anti PD-L2 agents are used in combination with one or more senolytic agents, the one or more senolytic agents can be administered at the same time (e.g., in a single composition containing both the one or more anti-PD-L2 agents and the one or more senolytic agents) or independently. For example, the one or more anti-PD-L2 agents can be administered first, and the one or more senolytic agents administered second, or vice versa. In some cases, a mammal (e.g., a human identified as having a senescence-related disease based, at least in part, on the presence of an elevated level of PD-L2) can be administered (or instructed to self-administer) one or more anti-PD-L2 agents and can be administered (or instructed to self-administer) one or more anti-TNFα agents. An anti- TNFα agent is an agent designed to inhibit or reduce the level or activity of TNFα within a mammal. Examples of anti-TNFα agents that can be used in the methods described herein include, without limitation, TNFα inhibitors such as etanercept, infliximab, adalimumab, certolizumab pegol, and golimumab. In cases where one or more anti PD-L2 agents are used in combination with one or more anti-TNFα agents, the one or more anti-TNFα agents can be administered at the same time (e.g., in a single composition containing both the one or more anti-PD-L2 agents and the one or more anti-TNFα agents) or independently. For example, the one or Attorney Docket No.07039-2219WO1 2023-151 more anti-PD-L2 agents can be administered first, and the one or more anti-TNFα agents administered second, or vice versa. In some cases, a mammal (e.g., a human identified as having a senescence-related disease based, at least in part, on the presence of an elevated level of PD-L2) can be administered (or instructed to self-administer) one or more anti-PD-L2 agents and can be administered (or instructed to self-administer) one or more NF-κB inhibitors. An NF-κB inhibitor is an agent designed to inhibit or reduce NF-κB activity within a mammal. Examples of NF-κB inhibitors that can be used in the methods described herein include, without limitation, bortezomib, curcumin, resveratrol, Bay 11-7082, TPCA-1, parthenolide, wedelolactone, celastrol, tanshinone IIA, and thymoquinone. In cases where one or more anti PD-L2 agents are used in combination with one or more NF-κB inhibitors, the one or more NF-κB inhibitors can be administered at the same time (e.g., in a single composition containing both the one or more anti-PD-L2 agents and the one or more NF-κB inhibitors) or independently. For example, the one or more anti-PD-L2 agents can be administered first, and the one or more NF-κB inhibitors administered second, or vice versa. In some cases, a mammal (e.g., a human identified as having a senescence-related disease based, at least in part, on the presence of an elevated level of PD-L2) can be administered (or instructed to self-administer) one or more anti-PD-L2 agents and can be administered (or instructed to self-administer) one or more MMP inhibitors. An MMP inhibitor is an agent designed to inhibit or reduce MMP activity within a mammal. Examples of MMP inhibitors that can be used in the methods described herein include, without limitation, marimastat (BB-2516), batimastat (BB-94), doxycycline, GM6001 (ilomastat), tetracyclines, collagen peptide-derived inhibitors, and tissue inhibitors of metalloproteinases (TIMPs). In cases where one or more anti PD-L2 agents are used in combination with one or more MMP inhibitors, the one or more MMP inhibitors can be administered at the same time (e.g., in a single composition containing both the one or more anti-PD-L2 agents and the one or more MMP inhibitors) or independently. For example, the one or Attorney Docket No.07039-2219WO1 2023-151 more anti-PD-L2 agents can be administered first, and the one or more MMP inhibitors administered second, or vice versa. In some cases, a mammal (e.g., a human identified as having a senescence-related disease based, at least in part, on the presence of an elevated level of PD-L2) can be administered (or instructed to self-administer) one or more anti-PD-L2 agents and can be administered (or instructed to self-administer) one or more gamma secretase inhibitors. A gamma secretase inhibitor is an agent designed to inhibit or reduce gamma secretase activity within a mammal. Examples of gamma secretase inhibitors that can be used in the methods described herein include, without limitation, semagacestat (LY450139), avagacestat (BMS-708163), RO4929097, MK-0752 (dibenzazepine), LY-411,575, and E2012 (ELND006). In cases where one or more anti PD-L2 agents are used in combination with one or more gamma secretase inhibitors, the one or more gamma secretase inhibitors can be administered at the same time (e.g., in a single composition containing both the one or more anti-PD-L2 agents and the one or more gamma secretase inhibitors) or independently. For example, the one or more anti-PD-L2 agents can be administered first, and the one or more gamma secretase inhibitors administered second, or vice versa. In some cases, the methods for treating a mammal (e.g., a mammal such as a human having a senescence-related disease) as described herein (e.g., by administering one or more anti-PD-L2 agents) also can include performing one or more (e.g., one, two, three, four, five, or more) additional therapies used to treat senescence-related conditions on the mammal. For example, when a method described herein is used to treat a mammal having cancer with one or more anti-PD-L2 agents, the method also can include performing or administering one or more (e.g., one, two, three, four, five, or more) additional therapies, (e.g., administration of an alkylating agent; a corticosteroid; a platinum drug; a purine analog; an anti-metabolite; an anthracycline; a chemotherapeutic agent; an immunotherapy such as a monoclonal antibody, antibody-drug conjugate, radioactive antibody, or bispecific antibody; an immune checkpoint inhibitor; a signal transduction inhibitor; a BTK inhibitor; an agent such as cyclophosphamide, chlorambucil, bendamustine, ifosfamide, prednisone, dexamethasone, cisplatin, Attorney Docket No.07039-2219WO1 2023-151 carboplatin, oxaliplatin, fludarabine, pentostatin, cladribine, cytarabine, gemcitabine, methotrexate, pralatrexate, doxorubicin, liposomal doxorubicin, vincristine, mitoxantrone, etoposide, bleomycin, metformin, or any combination thereof; or a therapy such as surgery (e.g., debulking), radiation therapy, bone marrow transplant, or a cell therapy such as a chimeric antigen receptor (CAR)-T cell therapy). In cases where one or more anti-PD-L2 agents are used in combination with one or more additional therapies used to treat a senescence-related disease, the one or more additional therapies can be performed at the same time or independently of the administration of the one or more anti-PD-L2 agents. For example, the one or more anti- PD-L2 agents can be administered before, during, or after the one or more additional therapies are administered or performed. In some cases, a course of treatment can be monitored as described herein. For example, the level of PD-L2 within a mammal (e.g., within biological samples obtained from the mammal) can be monitored over the course of treatment to determine whether or not the treatment is effective and / or remains effective over time. Thus, this document provides methods and materials for assessing senescence-related disease treatments as well as methods and materials for effectively using senescence-related disease treatments within mammals. For example, this document provides methods and materials for determining whether or not a particular senescence-related disease treatment administered to a mammal (e.g., a human) is effective (e.g., is effective to reduce the number of senescent cells within that mammal). In some cases, determining that a mammal (e.g., a human) has a reduced level of PD-L2 (e.g., a reduced level of a PD-L2 polypeptide, such as a secreted PD-L2 polypeptide) following administration of an senescence-related disease treatment as compared to the level of PD-L2 prior to being treated can indicate that that senescence-related disease treatment is effective in that mammal and can be continued as is (or with one or more slight alterations). In some cases, determining that a mammal (e.g., a human) does not have a reduced level of PD- L2 following administration of a senescence-related disease treatment, as compared to the level of PD-L2 prior to being administered the treatment can indicate that that senescence-related disease treatment is not effective in that mammal and can be Attorney Docket No.07039-2219WO1 2023-151 discontinued, altered in amount and / or frequency, or changed to a different type of anti- senescence treatment in that mammal. A mammal (e.g., a human) having been administered treatment for a senescence- related disease (e.g., having been administered one or more anti-PD-L2 agents) can be assessed to determine and / or classify the efficacy of the treatment. For example, a mammal (e.g., a human) having been administered an anti-PD-L2 agent can be assessed to determine whether or not the anti-PD-L2 agent is effective within that mammal by comparing the level of PD-L2 in a sample (e.g., secreted PD-L2 polypeptide in a blood sample, a plasma sample, or a urine sample) obtained from the mammal following the treatment to the level of PD-L2 in a comparable sample obtained from the mammal prior to the treatment. As described herein, for example, senescent cells within a mammal (e.g., a human) can secrete PD-L2 polypeptides that can be detected in that mammal’s bodily fluids (e.g., in that mammal’s blood or plasma) and / or tissues (e.g., tumor tissues). Accordingly, levels of PD-L2 polypeptides can be used to determine whether the number of senescent cells in a mammal (e.g., a human) are increasing, decreasing, or staying the same or essentially the same, and can therefore be used to determine and / or classify whether or not a senescence-related disease treatment is effective (e.g., whether or not an anti-senescence treatment reduced the number of senescent cells within the mammal). If a treatment for a senescence-related disease is determined to be effective, the same treatment can be administered to the mammal (e.g., human). In some cases, if a treatment for a senescence-related disease is determined to be effective, a treatment that is a slight modification of the original treatment can be administered to the mammal (e.g., human). For example, when a senescence-related disease treatment is determined to be effective within a mammal, that mammal can be administered or instructed to self- administer a slightly higher dose (e.g., 1.1x or 1.2x that of the original dose) or a slightly lower dose (e.g., 0.9x or 0.8x that of the original dose) of the same agent(s) of the effective treatment for the senescence-related disease. If a treatment for a senescence-related disease is determined and / or classified to not be effective, a revised treatment can be administered. For example, when a senescence-related disease treatment is determined not to be effective within a mammal, Attorney Docket No.07039-2219WO1 2023-151 that mammal can be administered or instructed to self-administer a revised treatment that includes (a) treatment with an anti-PD-L2 agent that is different from the previously administered anti-PD-L2 agent(s), (b) treatment with an anti-PD-L2 agent that is of a higher amount of the previously administered anti-PD-L2 agent, and / or (c) treatment that includes one or more additional agents (e.g., one or more senolytic agents) that were not previously administered in the senescence-related disease treatment. Any of the methods described herein used to determine if a senescence-related disease treatment is effective also can be used to determine if a revised treatment for the senescence-related disease is effective. A sample (e.g., a blood sample, a plasma sample, or a urine sample) can be obtained from a mammal (e.g., a human) before and / or after the mammal has been administered a senescence-related disease treatment (e.g., one or more anti-PD-L2 agents). In some cases, a sample (e.g., a blood sample, a plasma sample, or a urine sample) can be obtained from a mammal (e.g., a human) at any appropriate time before the mammal has been administered a senescence-related disease treatment and assessed to determine the level of PD-L2 (e.g., PD-L2 polypeptide) within the mammal prior to being administered the senescence-related disease treatment. For example, a sample (e.g., a blood sample, a plasma sample, or a urine sample) can be obtained from a mammal (e.g., a human) within five minutes, 30 minutes, one hour, six hours, 12 hours, one day, two days, three days, five days, one week, two weeks, three weeks, four weeks, on month, two months, three months, four months, six months, eight months, ten months, one year, two years, three years, or five years before the mammal has been administered a senescence-related disease treatment, and the sample can be assessed to determine the level of PD-L2 (e.g., PD-L2 polypeptide) within the mammal prior to being administered the senescence-related disease treatment. Such a determined level of PD-L2 within the mammal prior to being administered the senescence-related disease treatment can be used to determine if the level of PD-L2 within the mammal determined after the mammal has been administered a senescence-related disease treatment is reduced, is elevated, or remains the same following the treatment. A reduction in the level of PD-L2 (e.g., PD-L2 Attorney Docket No.07039-2219WO1 2023-151 polypeptide) within the mammal after the mammal has been administered a senescence- related disease treatment can indicate that the treatment was effective in that mammal. In some cases, a sample (e.g., a blood sample, a plasma sample, or a urine sample) can be obtained from a mammal (e.g., a human) during the time that the mammal is administered a senescence-related disease treatment and assessed to determine the level of PD-L2 (e.g., a PD-L2 polypeptide) within the mammal at that time. For example, a sample (e.g., a blood sample, a plasma sample, or a urine sample) can be obtained from a mammal (e.g., a human) at the same time that the mammal is being administered a senescence-related disease treatment (e.g., at the start of a senescence-related disease treatment) and assessed to determine the level of PD-L2 (e.g., a PD-L2 polypeptide) within the mammal at that time. Such a determined level of PD-L2 within the mammal at the time of administration of the senescence-related disease treatment can be used to determine if the level of PD-L2 within the mammal determined after the mammal has been exposed to the administered treatment for a period of time is reduced, is elevated, or remains the same following the treatment. A reduction in the level of PD-L2 (e.g., a PD- L2 polypeptide) within the mammal after the mammal has been exposed to the administered senescence-related disease treatment for a period of time can indicate that the senescence-related disease treatment is effective in that mammal. In some cases, to assess the effectiveness of an anti-senescence treatment within a mammal, a sample (e.g., a blood sample, a plasma sample, or a urine sample) can be obtained from the mammal (e.g., a human) at any appropriate time after the mammal has been administered an senescence-related disease treatment and assessed to determine the level of PD-L2 (e.g., a PD-L2 polypeptide) within the mammal after being administered the senescence-related disease treatment. For example, a sample (e.g., a blood sample, a plasma sample, or a urine sample) can be obtained from a mammal (e.g., a human) between about 1 day and about 8 weeks (e.g., about 1 to 7 days, about 1 to 2 weeks, about 2 to 4 weeks, about 4 to 6 weeks, or about 6 to 8 weeks) after an initial administration of a senescence-related disease treatment and assessed to determine the level of PD-L2 (e.g., a PD-L2 polypeptide) within the mammal after being administered the senescence-related disease treatment. Such a determined level of PD-L2 within the mammal after being Attorney Docket No.07039-2219WO1 2023-151 administered the senescence-related disease treatment can be used to determine if the level of PD-L2 (e.g., a PD-L2 polypeptide) within the mammal determined after the mammal has been administered an senescence-related disease treatment is reduced, is elevated, or remains the same following the treatment. A reduction in the level of PD-L2 within the mammal after the mammal has been administered a senescence-related disease treatment can indicate that the treatment was effective in that mammal. In some cases, the level of PD-L2 (e.g., a PD-L2 polypeptide) within a mammal (e.g., within a sample obtained from a mammal) can be detected at different time points over a course of a senescence-related disease treatment (and / or a revised senescence- related disease treatment) to determine the efficacy of the treatment (and / or revised treatment). For example, two or more (e.g., two, three, four, five, six, or more) samples (e.g., blood samples, plasma samples, or urine samples) can be obtained from a mammal at different time points over the course of a senescence-related disease treatment (and / or a revised senescence-related disease treatment), and the level of PD-L2 (e.g., a PD-L2 polypeptide) in the samples can be used to determine the efficacy of the treatment (and / or a revised treatment). In some cases, a first sample (e.g., a first blood sample, a first plasma sample, or a first urine sample) can be obtained from a mammal (e.g., a human) prior to the mammal being administered a senescence-related disease treatment (e.g., prior to being administered one or more anti-PD-L2 agents), and a second sample (e.g., a second blood sample, a second plasma sample, or a second urine sample), and optionally subsequent samples, can be obtained from the mammal after the mammal has been administered the senescence-related disease treatment. When the level of PD-L2 (e.g., a PD-L2 polypeptide) in the second sample is less than (e.g., at least 1, 2, 3, 4, 5, 10, 15, 20, 25, or 50 percent less than) the level of PD-L2 (e.g., a PD-L2 polypeptide) in the first sample, then the senescence-related disease treatment (e.g., one or more anti-PD-L2 agents) can be determined and / or classified as being an effective treatment for that mammal. When the level of PD-L2 (e.g., a PD-L2 polypeptide) in the second sample is greater than (e.g., at least 1, 2, 3, 4, 5, 10, 15, 20, 25, or 50 percent greater than) or equal to the level of PD- L2 (e.g., a PD-L2 polypeptide) in the first sample, then the treatment (e.g., one or more Attorney Docket No.07039-2219WO1 2023-151 anti-PD-L2 agents) can be determined and / or classified as not being an effective treatment for that mammal. Exemplary Embodiments Embodiment 1 is a method for classifying a mammal as having, or being likely to have, a senescence-related disease or condition, wherein the method comprises: detecting an elevated level of a secreted programmed cell death 1 ligand 2 (PD-L2) polypeptide in a biological fluid sample obtained from a mammal, and classifying the mammal as having the senescence-related disease or condition. Embodiment 2 is the method of embodiment 1, wherein the mammal is a human. Embodiment 3 is the method of embodiment 1 or embodiment 2, wherein the senescence-related disease or condition is a senescence-related cancer. Embodiment 4 is the method of embodiment 3, wherein the senescence-related cancer is a melanoma, a pancreatic adenocarcinoma, an osteosarcoma, a squamous cell carcinoma, a breast cancer, or a head and neck squamous cell carcinoma. Embodiment 5 is the method of embodiment 1 or embodiment 2, wherein the senescence-related disease or condition is selected from the group consisting of cardiovascular diseases, neurodegenerative diseases, pulmonary diseases, chronic inflammatory diseases, liver diseases, kidney diseases, eye diseases, skin diseases, vascular diseases, musculoskeletal disorders, metabolic disorder, immune system dysfunction, osteoarthritis, type 2 diabetes, and age-related hearing loss. Embodiment 6 is the method of any one of embodiments 1 to 5, wherein the biological fluid sample comprises whole blood, plasma, or serum. Embodiment 7 is the method of any one of embodiments 1 to 6, wherein the elevated level of the secreted PD-L2 polypeptide is as compared to a reference level of the secreted PD-L2 polypeptide present in biological fluid samples from controls known not to have the senescence-related disease or condition. Embodiment 8 is the method of any one of embodiments 1 to 7, wherein the detecting comprises using an anti-PD-L2 antibody to detect the elevated level of the secreted PD-L2 polypeptide. Attorney Docket No.07039-2219WO1 2023-151 Embodiment 9 is a method for treating a mammal having a senescence-related disease or condition, wherein the method comprises: (a) identifying the mammal as having a biological fluid sample comprising the presence of an elevated level of secreted PD-L2; and (b) administering to the mammal a treatment for the senescence-related disease or condition. Embodiment 10 is the method of embodiment 9, wherein the mammal is a human. Embodiment 11 is the method of embodiment 9 or embodiment 10, wherein the senescence-related disease or condition is a senescence-related cancer. Embodiment 12 is the method of embodiment 11, wherein the senescence-related cancer is a melanoma, a pancreatic adenocarcinoma, an osteosarcoma, a squamous cell carcinoma, a breast cancer, or a head and neck squamous cell carcinoma. Embodiment 13 is the method of embodiment 9 or embodiment 10, wherein the senescence-related disease or condition is selected from the group consisting of cardiovascular diseases, neurodegenerative diseases, pulmonary diseases, chronic inflammatory diseases, liver diseases, kidney diseases, eye diseases, skin diseases, vascular diseases, musculoskeletal disorders, metabolic disorder, immune system dysfunction, osteoarthritis, type 2 diabetes, and age-related hearing loss. Embodiment 14 is the method of any one of embodiments 9 to 13, wherein the biological fluid sample comprises whole blood, plasma, or serum. Embodiment 15 is the method of any one of embodiments 9 to 14, wherein the elevated level of secreted PD-L2 is as compared to a reference level present in controls known not to have the senescence-related disease or condition. Embodiment 16 is the method of any one of embodiments 9 to 15, wherein the identifying comprises using an anti-PD-L2 antibody to detect the elevated level of the secreted PD-L2 polypeptide in the sample. Embodiment 17 is the method of any one of embodiments 9 to 16, wherein the treatment comprises an anti-PD-L2 agent, a senolytic agent, an anti-tumor necrosis factor alpha (TNFα) agent, an NF-κB inhibitor, a matrix metalloprotease (MMP) inhibitor, a gamma secretase inhibitor, or any combination thereof. Attorney Docket No.07039-2219WO1 2023-151 Embodiment 18 is a method for treating a mammal having a senescence-related disease or condition, wherein the method comprises administering, to a mammal identified as having a biological fluid sample comprising the presence of an elevated level of secreted PD-L2, a treatment for the senescence-related disease or condition. Embodiment 19 is the method of embodiment 18, wherein the mammal is a human. Embodiment 20 is the method of embodiment 18 or embodiment 19, wherein the senescence-related disease or condition is a senescence-related cancer. Embodiment 21 is the method of embodiment 20, wherein the senescence-related cancer is a melanoma, a pancreatic adenocarcinoma, an osteosarcoma, a squamous cell carcinoma, a breast cancer, or a head and neck squamous cell carcinoma. Embodiment 22 is the method of embodiment 18 or embodiment 19, wherein the senescence-related disease or condition is selected from the group consisting of cardiovascular diseases, neurodegenerative diseases, pulmonary diseases, chronic inflammatory diseases, liver diseases, kidney diseases, eye diseases, skin diseases, vascular diseases, musculoskeletal disorders, metabolic disorder, immune system dysfunction, osteoarthritis, type 2 diabetes, and age-related hearing loss. Embodiment 23 is the method of any one of embodiments 18 to 22, wherein the biological fluid sample comprises whole blood, plasma, or serum. Embodiment 24 is the method of any one of embodiments 18 to 23, wherein the elevated level of secreted PD-L2 is as compared to a reference level present in controls known not to have the cancer. Embodiment 25 is the method of any one of embodiments 18 to 24, wherein the mammal was identified as having an elevated level of PD-L2 polypeptide in the biological fluid sample by using an anti-PD-L2 antibody to detect the elevated level of the secreted PD-L2 polypeptide. Embodiment 26 is the method of any one of embodiments 18 to 25, wherein the treatment comprises an anti-PD-L2 agent, a senolytic agent, an anti-TNFα agent, an NF- κB inhibitor, a MMP inhibitor, a gamma secretase inhibitor, or any combination thereof. Attorney Docket No.07039-2219WO1 2023-151 Embodiment 27 is a method for assessing the efficacy of a treatment in a mammal having a senescence-related disease or condition, wherein the method comprises: determining a first level of PD-L2 in a first biological sample obtained from the mammal prior to administration of the treatment; administering the treatment to the mammal; determining a second level of PD-L2 in a second biological sample obtained from the mammal after administration of the treatment; and when the second level of PD-L2 is lower than the first level of PD-L2, determining that the treatment is effective, or when the second level of PD-L2 is not lower than the first level of PD-L2, determining that the treatment is not effective. Embodiment 28 is the method of embodiment 27, wherein the mammal is a human. Embodiment 29 is the method of embodiment 27 or embodiment 28, wherein the senescence-related disease or condition is a senescence-related cancer. Embodiment 30 is the method of embodiment 29, wherein the senescence-related cancer is a melanoma, a pancreatic adenocarcinoma, an osteosarcoma, a squamous cell carcinoma, a breast cancer, or a head and neck squamous cell carcinoma. Embodiment 31 is the method of embodiment 27 or embodiment 28, wherein the senescence-related disease or condition is selected from the group consisting of cardiovascular diseases, neurodegenerative diseases, pulmonary diseases, chronic inflammatory diseases, liver diseases, kidney diseases, eye diseases, skin diseases, vascular diseases, musculoskeletal disorders, metabolic disorder, immune system dysfunction, osteoarthritis, type 2 diabetes, and age-related hearing loss. Embodiment 32 is the method of any one of embodiments 27 to 31, wherein the first and second biological samples are biological fluid samples, and wherein the PD-L2 is a secreted PD-L2 polypeptide. Embodiment 33 is the method of embodiment 32, wherein the first and second biological fluid samples comprise whole blood, plasma, or serum. Embodiment 34 is the method of embodiment 32 or embodiment 33, wherein the determining comprises detecting a level of secreted PD-L2 polypeptide in the first and second biological fluid samples. Attorney Docket No.07039-2219WO1 2023-151 Embodiment 35 is the method of any one of embodiments 27 to 34, wherein the elevated level of PD-L2 is as compared to a reference level present in controls known not to have the senescence-related disease or condition. Embodiment 36 is the method of any one of embodiments 27 to 35, wherein the treatment comprises an anti-PD-L2 agent, a senolytic agent, an anti-TNFα agent, an NF- κB inhibitor, a MMP inhibitor, a gamma secretase inhibitor, or any combination thereof. Embodiment 37 is a method for treating a senescence-related disease or condition in a mammal, wherein the method comprises: administering, to a mammal having a senescent-related disease or condition and identified as having a biological sample containing an elevated level of PD-L2, (a) an anti-TNFα therapy, an NF-κB inhibitor, or an anti-TNFα and an NF-κB inhibitor, and (b) an anti-PD-L2 agent. Embodiment 38 is the method of embodiment 37, wherein the mammal is a human. Embodiment 39 is the method of embodiment 37 or embodiment 38, wherein the senescence-related disease or condition is a senescence-related cancer. Embodiment 40 is the method of embodiment 39, wherein the senescence-related cancer is a melanoma, a pancreatic adenocarcinoma, an osteosarcoma, a squamous cell carcinoma, a breast cancer, or a head and neck squamous cell carcinoma. Embodiment 41 is the method of embodiment 37 or embodiment 38, wherein the senescence-related disease or condition is selected from the group consisting of cardiovascular diseases, neurodegenerative diseases, pulmonary diseases, chronic inflammatory diseases, liver diseases, kidney diseases, eye diseases, skin diseases, vascular diseases, musculoskeletal disorders, metabolic disorder, immune system dysfunction, osteoarthritis, type 2 diabetes, and age-related hearing loss. Embodiment 42 is the method of any one of embodiments 37 to 41, wherein the biological sample is a biological fluid sample, and wherein the PD-L2 is a secreted PD- L2 polypeptide. Embodiment 43 is the method of embodiment 42, wherein the biological fluid sample comprises whole blood, plasma, or serum. Attorney Docket No.07039-2219WO1 2023-151 Embodiment 44 is the method of any one of embodiments 37 to 43, wherein the elevated level of PD-L2 is as compared to a reference level present in controls known not to have the senescence-related disease or condition. Embodiment 45 is the method of any one of embodiments 37 to 44, comprising administering the anti-TNFα therapy. Embodiment 46 is the method of embodiment 45, wherein the anti-TNFα therapy is selected from the group consisting of etanercept, infliximab, adalimumab, certolizumab pegol, and golimumab. Embodiment 47 is the method of any one of embodiments 37 to 46, comprising administering the NF-κB inhibitor. Embodiment 48 is the method of embodiment 47, wherein the NF-κB inhibitor is selected from the group consisting of bortezomib, curcumin, resveratrol, Bay 11-7082, TPCA-1, parthenolide, wedelolactone, celastrol, tanshinone IIA, and thymoquinone. Embodiment 49 is the method of any one of embodiments 37 to 48, wherein the anti-PD-L2 agent comprises an anti-PD-L2 antibody. Embodiment 50 is a method for treating a senescence-related disease or condition in a mammal, wherein the method comprises: administering, to a mammal having a senescence-related disease or condition and identified as having a biological sample containing an elevated level of PD-L2, (a) an MMP inhibitor, a gamma secretase inhibitor, or an MMP inhibitor and a gamma secretase inhibitor, and (b) an anti-PD-L2 agent, a senolytic agent, or an anti-PD-L2 agent and a senolytic agent. Embodiment 51 is the method of embodiment 50, wherein the mammal is a human. Embodiment 52 is the method of embodiment 50 or embodiment 51, wherein the senescence-related disease or condition is a senescence-related cancer. Embodiment 53 is the method of embodiment 52, wherein the senescence-related cancer is a melanoma, a pancreatic adenocarcinoma, an osteosarcoma, a squamous cell carcinoma, a breast cancer, or a head and neck squamous cell carcinoma. Embodiment 54 is the method of embodiment 50 or embodiment 51, wherein the senescence-related disease or condition is selected from the group consisting of Attorney Docket No.07039-2219WO1 2023-151 cardiovascular diseases, neurodegenerative diseases, pulmonary diseases, chronic inflammatory diseases, liver diseases, kidney diseases, eye diseases, skin diseases, vascular diseases, musculoskeletal disorders, metabolic disorder, immune system dysfunction, osteoarthritis, type 2 diabetes, and age-related hearing loss. Embodiment 55 is the method of any one of embodiments 50 to 54, wherein the biological sample is a biological fluid sample, and wherein the PD-L2 is a secreted PD- L2 polypeptide. Embodiment 56 is the method of embodiment 55, wherein the biological fluid sample comprises whole blood, plasma, or serum. Embodiment 57 is the method of any one of embodiments 50 to 56, wherein the elevated level of PD-L2 is as compared to a reference level present in controls known not to have the senescence-related disease or condition. Embodiment 58 is the method of any one of embodiments 50 to 57, comprising administering the MMP inhibitor. Embodiment 59 is the method of embodiment 58, wherein the MMP inhibitor is selected from the group consisting of marimastat (BB-2516), batimastat (BB-94), doxycycline, GM6001 (ilomastat), tetracyclines, collagen peptide-derived inhibitors, and tissue inhibitors of metalloproteinases (TIMPs). Embodiment 60 is the method of any one of embodiments 50 to 59, comprising administering the gamma secretase inhibitor. Embodiment 61 is the method of embodiment 60, wherein the gamma secretase inhibitor is selected from the group consisting of semagacestat (LY450139), avagacestat (BMS-708163), RO4929097, MK-0752 (dibenzazepine), LY-411,575, and E2012 (ELND006). Embodiment 62 is the method of any one of embodiments 50 to 61, comprising administering the anti-PD-L2 agent. Embodiment 63 is the method of embodiment 62, wherein the anti-PD-L2 agent comprises an anti-PD-L2 antibody. Embodiment 64 is the method of any one of embodiments 50 to 63, comprising administering the senolytic agent. Attorney Docket No.07039-2219WO1 2023-151 Embodiment 65 is the method of embodiment 64, wherein the senolytic agent is selected from the group consisting of dasatinib, quercetin, navitoclax, A1331852, A1155463, fisetin, luteolin, geldanamycin, tanespimycin, alvespimycin, piperlongumine, panobinostat, FOX04-related peptides, nutlin3a, ruxolitinib, metformin, rapamycin, JAK1 / 2 inhibitors, NF-κB inhibitors, p38 inhibitors, IL-6 inhibitors, and STAT3 inhibitors. The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims. EXAMPLES Example 1 – Efficacy of chemotherapy is limited by intratumoral senescent cells that persist through the upregulation of PD-L2 Methods and Materials Mammalian tissue culture: SK-MEL-28 (human melanoma) and panc1 (human pancreatic adenocarcinoma) cells were obtained from American Type Culture Collection. Cells were routinely tested for mycoplasma contamination. Cells were maintained in Dulbecco’s Modified Eagle’s Medium (GIBCO®). All media were supplemented with 10% fetal bovine serum (GIBCO®) with 1% penicillin / streptomycin (GIBCO®). All cell lines were cultured at 37°C in a humidified atmosphere and 5% CO2. Induction of cellular senescence in tissue culture and treatments with IKK inhibitor and TNFα ^ ^Unless otherwise noted, senescence was induced using 5 μM palbociclib (Pfizer Inc.) for seven days, or 48 hour treatments with 200 nM doxorubicin (Sigma-Aldrich) and 12 mU bleomycin (Sigma-Aldrich), after which fresh media was added. Senescence was evaluated at day 7. For κB kinase (IKK) inhibition, cells were treated at days 2 and 6 with either vehicle (DMSO) or the κB kinase inhibitor BAY 11- 7082 (Selleckchem) at 3 ^M for 24 hours. Human TNFα Recombinant Protein (Thermo Fisher Scientific) was used at 100 ng / mL for 3 days. For gene expression determination after IKK and TNFα treatments, RNA was isolated using TRIZOL™ (Thermo Fisher Scientific; Waltham, MA) according to the manufacturer’s instructions. cDNA was generated using 1 ^g of RNA using M-MLV Reverse Transcriptase (Thermo Fisher Scientific) according to the manufacturer’s Attorney Docket No.07039-2219WO1 2023-151 instructions. qPCR was performed using the TAQMAN®Fast Advanced Master Mix (Thermo Fisher Scientific) on QUANTSTUDIO™ 7 Pro (Thermo Fisher Scientific). TBP was used as housekeeping gene. The assays used Human TBP taqman probe Hs00427620_m1, Human PD-L1 taqman probe Hs01125299_m1, and Human PD-L2 taqman probe Hs01057775_m1 (all from Thermo Fisher Scientific). Flow cytometry: Cells were harvested in PBS with 10 mM EDTA at 37°C. Collected cells were stained with yellow live / dead dye solution (Invitrogen) for 15 minutes at 4°C and washed. Cells were then stained with anti-PD-L2-biotin (Miltenyi Biotec #130-098-525) diluted 1:11 in FACS buffer (0.5% BSA, 2 mM EDTA in PBS) for 15 minutes, and after two washes the samples were incubated for 15 minutes with anti- biotin-APCVio770 (Miltenyi Biotec #130-113-851) diluted 1:50 in FACS buffer. After repeated washes, cells were filtered using a 70 μm cell strainer and analyzed on a Gallios flow cytometer and with FlowJo 10.0.7. CRISPR: For PD-L2 knockouts, mouse and human sgRNAs (TABLE 1) were designed using the CHOPCHOP web tool (chopchop.cbu.uib.no) and cloned into lentiCRISPRv2 (Addgene #52961). TABLE 1: sgRNAs targeting human (h) or mouse (m) PD-L2 genes Primer Sequence SEQ ID NO Generation of lentiviruses and infections: Lentiviruses were produced by transfecting HEK293T cells with p8.91 (gag-pol expressor), pMDG.2 (VSV-G expressor) and lentiCRISPRv2 (Addgene #52961) for generation of bulk PD-L2-KO cells. Virus batches were harvested 48, 72, and 96 hours after transfection. Cellular debris was removed by centrifugation and filtering. The supernatant containing the virus was then used fresh or stored by snap-freezing aliquots supplemented with 8 μg / mL polybrene (Fisher Scientific) in ethanol / dry ice and stored at -80°C. Recipient cells were incubated for eight hours with lentivirus and selected three days later with puromycin (Merck) for lentiCRISPRv2 experiments. Attorney Docket No.07039-2219WO1 2023-151 Results Effects of NF-κB and TNFα on PD-L2 expression: A conserved feature of cellular senescence is the constitutive hyperactivation of the transcription factor NF-kB, which is a key driver of the SASP (Chien et al., Genes Dev, 25:2125-2136 (2011); and Freund et al., EMBO J, 30:1536-1548 (2011)). Blunting NF-kB signaling by inhibition of its upstream activator, IKK, in human melanoma (SK-MEL-28) and pancreatic adenocarcinoma (Panc1) senescent cells resulted in a marked decrease of PD-L2 mRNA levels, while PD-L1 expression was largely unaffected (FIGS.1A and 2A). Incubation of these human cancer cell lines with TNFα, which activates NF- ^B, induced PD-L2 expression to a larger extent than PD-L1 (FIGS.1B and 2B). Together, these data demonstrated that NF- ^B signaling differentially governs PD-L2 and PD-L1 mRNA levels in accordance with the expression patterns observed upon senescence induction. Example 2 – PD-L2 is upregulated in senescent cells Human preadipocytes were rendered senescent by 20Gy X-ray irradiation. Two months later, expression of PD-L2, PD-L1, p16, and p21 was assessed by RT-qPCR (FIG.3A) using Human TBP taqman probe Hs00427620_m1, Human PD-L1 taqman probe Hs01125299_m1, Human PD-L2 taqman probe Hs01057775_m1, and P16 INK4a customized (PN4332078), all from ThermoFisher Scientific. Human preadipocytes also were rendered senescent by Doxorubicin (24 hours / 200 nM).14 days later, expression of PD-L2 and PD-L1 was assessed by RT-qPCR (FIG.3B). In addition, human preadipocytes were rendered senescent by serial passaging. After 18 passages, RNA was harvested and expression of PD-L2, PD-L1 and p16 was assessed by RT-qPCR (FIG. 3C). HUVEC were rendered senescent by doxorubicin (24 hours / 400 nM) or irradiation (10Gy).14 days later, PD-L2 and PD-L1 expression was assessed by RT-qPCR (FIG. 3D). Human renal glomerular endothelial cells were rendered senescent by doxorubicin (24 hours / 200 nM) or irradiation (10Gy).14 days later PD-L2 and PD-L1 expression was assessed by RT-qPCR (FIG.3E). HUVEC WT and CRISPR-generated PD-L2KO cells were rendered senescent by doxorubicin (24 hours / 400 nM) or irradiation (10Gy). After Attorney Docket No.07039-2219WO1 2023-151 14 days, PD-L2 expression on the cell membrane was assessed by flow cytometry (FIG. 3F). MDA-MB-231, MDA-468, and HS-578 cells (all from human breast cancer cell lines) were rendered senescent by doxorubicin (48 hours / 50 nM). After 7 days, PD-L2 expression assessed by RT-qPCR (FIG.3G). These studies demonstrated that PD-L2 was significantly upregulated in the senescent cells, suggesting that PD-L2 can be targeted as a therapeutic strategy for senescence-related diseases and that PD-L2 can be used as a diagnostic tool to identify senescent cells. Example 3 – Senescent cells secrete PD-L2, which is regulated via proteolytic cleavage Human preadipocytes were rendered senescent by serial passaging. Conditioned media was collected from passage 9 and passage 18 cells, and levels of secreted PD-L2 and PD-L1 were assessed using the Human PROCARTAPLEX™ Simplex Kit (Thermo Fisher) (FIG.4A). The amount of secreted PD-L2 in media from HUVEC WT and CRISPR generated PD-L2KO cells was measured (FIG.4B). Senescence in HUVEC was induced by 10Gy x-ray irradiation, and after 7 days, vehicle, MMP inhibitor (selleckchem / Ilomastat), proteinase inhibitor (Sigma / P1860), or gamma secretase inhibitor (selleckchem / Avagacestat) was added to the cells. After 48 hours of incubation, media were changed to inhibitor-containing, serum-free media for 24 hours, and then conditioned media was collected for measurement of secreted PD-L2 levels using the Human PROCARTAPLEX™ Simplex Kit (FIG.4C). IMR90 and MDA-MB-231 cells were rendered senescent by doxorubicin, and levels of secreted PD-L2 were measured after 7 days (MDA-MB-231) or 3 weeks (IMR90). Conditioned media were collected after 24 hours of incubation in serum-free media to measure secreted PD-L2 levels using the Human PROCARTAPLEX™ Simplex Kit (FIG.4D). These studies demonstrated that shedding of the PD-L2 ectodomain (resulting in sPD-L2) is regulated through proteases such as MMPs and gamma secretase, and that inhibiting MMPs and gamma secretase reduced levels of sPD-L2 in conditioned media of cultured cells. These finding suggested that targeting MPPs, gamma secretase, and other proteinases is a therapeutic option to reduce sPD-L2 levels, that sPD-L2 can be used as a biomarker to stratify patients to anti-PD-L2 agent. Attorney Docket No.07039-2219WO1 2023-151 Example 4 – PD-L2 is regulated through the NF-κB pathway HUVEC were treated with doxorubicin (400 nM) for 2 days. Thereafter, cells were incubated with media containing either vehicle or an IKK inhibitor (3 µM BAY 11- 7082). After 24 hours, RNA was harvested and expression of PD-L2 and PD-L1 was assessed by RT-qPCR (FIG.5A). SK-Mel28 cells were treated with doxorubicin (50 nM) for 2 days, after which the media was changed to drug free media. On day 6, cells were incubated with media containing either vehicle or IKK inhibitor (3µM BAY 11-7082). After 24 hours, RNA was harvested and expression of PD-L2 and PD-L1 was assessed (FIG.5B). Panc1 cells were treated with doxorubicin (50 nM) for 2 days, after which the media was changed to drug free media. On day 6, cells were incubated with media containing either vehicle or IKK inhibitor (3µM BAY 11-7082). After 24 hours, RNA was harvested and expression of PD-L2 and PD-L1 was measured (FIG.5C). HUVEC were treated with recombinant TNFα for 2 days, after which the media was replaced with media containing an IKK inhibitor (3µM BAY 11-7082). After 24 hours, RNA was harvested for assessment of PD-L2 and PD-L1 expression (FIG.5D). SK-Mel28 cells were treated with recombinant TNFα for 3 days, after which RNA was harvested to assess PD-L2 and PD-L1 expression (FIG.5E). Panc1 cells were treated with recombinant TNFα (Thermo Fisher / PHC3015) for 3 days, after which RNA was harvested and PD-L2 and PD-L1 expression was assessed (FIG.5F). These studies demonstrated that TNFα upregulated PD-L2 expression in normal and cancer cells, and indicated that PD-L2 expression is regulated by the NF-κB pathway and that an NF-κB inhibitor can block PD-L2 induction once cells become senescent or are treated with TNFα. In addition, these findings suggested targeting TNFα and / or NF-κB as a therapeutic strategy to reduce PD-L2 expression in order to enhance immune clearance of senescent cells in cancer and age / senescence-related diseases. Example 5 – PD-L2 regulation by the miR-17-92 cluster HUVEC were rendered senescent using doxorubicin (24 hours / 400 nM). After 14 days, expression levels of miRNA-20a, miRNA-106a and miRNA-106b were assessed by Attorney Docket No.07039-2219WO1 2023-151 RT-qPCR (FIG.6A) using hsa-miR-106a-5p miRCURY LNA miRNA Probe PCR Assay (ZP00000043), hsa-miR-20a-5p miRCURY LNA miRNA Probe PCR Assay (ZP00000422), and hsa-miR-106b-5p miRCURY LNA miRNA Probe PCR Assay (ZP00000045) (all from Qiagen). The livers of 27-month and 5-month-old male mice were assayed for PD-L2, PD-L1, p21, p16, miRNA-20a, miRNA-106a, and miRNA-106b by RT-qPCR (FIG.6B). HUVEC were rendered senescent using doxorubicin (24 hours / 400 nM), and 12 days later were transfected with 5 nM miRNA-20a mimic, miRNA-106a mimic, or miRNA-106b mimic. Two days later, RNA was harvested and expression of PD-L2, PD-L1, p21, and p16 was measured (FIG.6C). These studies demonstrated that the 3′UTR of PD-L2 and p21 have both binding sites for miRNAs of the miR-17-92 cluster, which are downregulated in senescent cells. Restoring these miRNAs downregulated PD-L2 expression as well as p21 expression, indicating that PD- L2 and the senescence gene p21 are regulated through the same pathway, and suggesting increased expression of these miRNAs as a therapeutic strategy to downregulate PD-L2 for cancer and age / senescence-related diseases. Example 6 – Increased levels of sPD-L2 in senescent associated pathologies Aged and gender matched plasma samples from healthy and obese human patients were assayed for secreted PD-L2 and PD-L1 using the Human PROCARTAPLEX™ Simplex Kit (FIG.7), revealing that levels of sPD-L2 were increased in plasma of obese patients compared to age and gender matched non-obese patients. These findings suggested targeting / measuring sPD-L2 as a therapeutic and diagnostic strategy for cancer and age / senescent-related diseases. Example 7 – Senolytics target PD-L2 high expressing senescent cells Human preadipocytes were rendered senescent by 20Gy irradiation. One month later, cells were treated with vehicle or with the senolytic combination of Dasatinib plus Quercetin (D+Q) for 3 days (Q 20 µM + D 400 nM). After 2 days of recovery, the remaining cells were harvested and expression of PD-L2 and PD-L1 was assessed by RT- qPCR (FIG.8A) using Human TBP taqman probe Hs00427620_m1, Human PD-L1 Attorney Docket No.07039-2219WO1 2023-151 taqman probe Hs01125299_m1, and Human PD-L2 taqman probe Hs01057775_m1 (all from ThermoFisher Scientific). Human adipose tissue explants were incubated with 20 μM Q and 1 μM D or vehicle. After 48 hours, the adipose explants were washed 3 times with PBS, RNA was harvested, and expression of PD-L2 and PD-L1 was assessed by RT-qPCR (FIG.8B). Plasma samples were obtained from idiopathic pulmonary fibrosis (IPF) patients before and after treatment with senolytics (D+Q). Plasma samples were assayed for secreted PD-L2 and PD-L1 using the Human PROCARTAPLEX™ Simplex Kit (FIG.8C). These studies demonstrated that senolytics (which pharmacologically eliminate senescent cells) can selectively target PD-L2 high expressing senescent cells in vitro and ex vivo, and that plasma levels of sPD-L2 were decreased after senolytic treatment of patients with IPF. These findings suggested that PD-L2 / sPD-L2 can be used as a biomarker to assess senescent cell burden, stratify patients to anti-aging therapies and immunotherapy, assess target engagement, and monitor disease severity and progression. Example 8 – PD-L2 increased in senescent associated pathologies IHC was used to assess the percentage PD-L2 positive area in adipose tissue of young and old human subjects (FIGS.9A and 9B), revealing that the PD-L2 positive area was increased in adipose tissue from older humans. Thus, consistent with the finding that PD-L2 is expressed by senescent cells in pathologies in which senescent cells accumulate, increased levels of PD-L2 were observed in adipose tissue biopsies from older patients compared to young patients. These findings suggested PD-L2 as a used diagnostic biomarker for age / senescent-related diseases. Example 9 – Survival curve of aged male and female PD-L2 WT and PD-L2 KO mice Survival of WT and PD-L2KO mice was assessed over the course of 2 years (FIG.10), revealing sex-specific differences of aged PD-L2WT and PD-L2KO mice. While male PD-L2KO lived longer compared to PD-L2WT mice, female PD-L2KO mice had a shorter lifespan compared to PD-L2WT mice. Example 10 – PD-L2KO mice display improved metabolic health Attorney Docket No.07039-2219WO1 2023-151 Glucose tolerance tests (FIGS.11A and 11B) and insulin tolerance tests (FIGS. 11C and 11D) were carried out in male 24-month-old PD-L2WT and PD-L2KO mice, revealing that old male PD-L2KO mice had improved insulin sensitivity compared to old PD-L2WT mice. These findings suggested anti-PD-L2 as a therapeutic option to improve insulin sensitivity in elderly males, and also suggested that immunotherapy may display sex differences. Example 11 – Anti-PD-L2 target p16 high expressing cells in human explant cultures Human adipose tissue explants from healthy (FIG.12A) or obese (FIG.12B) subjects were harvested and incubated with IgG isotype control antibodies or with anti- PD-L2 antibodies, and p16 expression was assessed 24 hours later by RT-qPCR using Human TBP taqman probe Hs00427620_m1 and P16 INK4a customized PN4332078 (ThermoFisher Scientific). These studies showed that treating human adipose tissue explants from obese subjects with anti-PD-L2 agent reduced p16 expression, and that this effect was lost in the explants from healthy subjects. This suggested anti-PD-L2 agents as a therapeutic option to eliminate senescent cells in senescence-associated diseases and / or chemotherapy-treated tumors. Example 12 – Older PD-L2KO mice show reduced senescent cell accumulation mRNA levels of PD-L2, p16, p21, OAS2, TNFα, MMP9, CCL5, and OAS3 in the livers of young (4 month-old) and old (26 month-old) male WT and KO mice were measured (FIG.13), demonstrating that older KO mice had reduced expression of these senescent cell and proinflammatory markers. Example 13 - sPD-L2 levels increase in plasma samples from older human patients Plasma samples from young (20 to 34 years of age) and old (65 to 84 years of age) humans were assessed for levels of sPD-L2, sPD-L1, several MMPs, and TNFα- related proteins (FIG.14). These studies revealed increased levels of sPD-L2, sPD-L1, some MMPs, and TNFα-related proteins in plasma samples from older humans. Attorney Docket No.07039-2219WO1 2023-151 Example 14 – Blocking PD-L2 prevents senescent cell accumulation and age-related dysfunction The results in Example 14 re-present and expand on at least some of the results provided in other Examples. Methods and Materials Animal studies: PD-L2KO mice (B6N.129(Cg)-Pdcd1lg2tm2Dmp / J) were obtained from The Jackson Laboratory (JAX:017515) (Shin et al., J Exp Med., 201:1531- 1541, 2005). Retained loxP-flanked neomycin resistance cassette was removed by crossing mice with sox2-cre recombinase strain (JAX: 008454). Mice were then backcrossed at least ten generations to C57BL / 6J (JAX:000664), and homozygous PD- L2WT and PD-L2KO colonies were established. Mice were regularly backcrossed. Old wild-type C57BL / 6J mice were obtained from the National Institute on Aging (NIA). Mice were housed in ventilated cages and maintained in a pathogen-free facility with constant temperature (23-24°C), a twelve-hour light / dark cycle, and access to food and water ad libitum. Cages and bedding were changed every other week. Cell culture: Human preadipocytes (also referred to as “adipose-derived stem cells” or “adipocyte progenitors”) were isolated from abdominal subcutaneous fat biopsies from gastric bypass surgery or from kidney donors as described elsewhere (Tchkonia et al., Am J Physiol Endocrinol Metab., 288:E267-277, 2005; and Tchkonia et al., Am J Physiol Endocrinol Metab., 292:E298-307, 2007), or biopsies from these subjects were used for human adipose tissue explant culture as described elsewhere (Xu et al., Nat Med., 24:1246-1256, 2018). Cells were cultured in alpha MEM (Gibco) with 10% fetal bovine serum (Gibco), 1% penicillin (Gibco), and 1% streptomycin (Gibco). HEK293T cells were obtained from ATCC (#CRL-3216) and maintained in DMEM (Gibco) with 10% fetal bovine serum, 1% penicillin, and 1% streptomycin. Human umbilical vein endothelial cells (HUVEC) were obtained from Lonza (#C2519A) and cultured in manufacturer-recommended growth medium (#CC-3162). The HUVEC-NF- κB-GFP reporter cell line was created by infecting HUVEC with lentiviruses to integrate an NFkB-GFP reporter following the manufacturer’s recommendation (#LVP965-P, Attorney Docket No.07039-2219WO1 2023-151 Gentarget). Human renal glomerular endothelial cells (HRGEC) were obtained from ScienCell Research Laboratories (#4000) and maintained in manufacturer-recommended growth medium (#1001). Ear fibroblasts were isolated as described elsewhere (Jurk et al., Nat Commun., 2:4172, 2014) and cultured in Advanced DMEM / F-12 (Gibco) plus 10% fetal bovine serum and 1% L-glutamine (Gibco), 1% penicillin, and 1% streptomycin. All cells were maintained in a humidified incubator at 37°C under atmospheric oxygen at 5% CO2, except for mouse ear fibroblasts which were cultured in 3% oxygen. Cell culture treatments: Human preadipocytes were rendered senescent by 20 Gy X-ray irradiation, 200 nM doxorubicin treatment for 24 hours, or serial subculturing to passage 18, and were assayed at the times indicated in the figure descriptions. HRGECs and HUVECs were rendered senescent by 10 Gy X-ray irradiation or 200 nM / 400 nM doxorubicin (#D1515, Sigma-Aldrich) for 24 hours, and were assayed at the times indicated in the figure descriptions. For TNF-α (#PHC3011, Gibco) and IκK inhibitor (BAY 11-7082, #S2913, Selleck Chemicals) experiments, cells were incubated for 2 days with 100 ng / ml recombinant TNF-α and then another 24 hours with 3 μM BAY 11-7082 or vehicle (DMSO) before being harvested for further analysis. For IFN-γ (#PHC4031, Gibco) experiments, cells were incubated for 3 days with 100 ng / ml recombinant IFN-γ before being harvested for further analysis. For MMP inhibition using Ilomastat (#S7157, Selleck Chemicals), 0.15x106senescent cells were cultured in complete media containing MMPi or DMSO for two days before changing the media to MMPi containing serum free media, and were then further cultured for 24 hours before the media were processed for further analysis. For senolytic experiments 0.15x106cells were rendered senescent and treated with either DMSO or 400 nM Dasatinib (#D-3307, LC Laboratories) + 20 μM Quercetin (#Q4951, Sigma-Aldrich) as described elsewhere (Zhu et al., Aging Cell, 14:644-658, 2015). After three days, the cells were washed three times and further cultured for two days in drug free media. The remaining cells were then processed for further analysis. Ex vivo senolytic treatment / adipose tissue explants: Adipose tissue explants were generated and treated with vehicle (DMSO) or Dasatinib (1 μM) + Quercetin (20 μM) as described elsewhere (Xu et al., Nat Med.24:1246-1256, 2018). Attorney Docket No.07039-2219WO1 2023-151 Gene expression analysis: TRIzol (Invitrogen) was used to extract RNA from cells and tissues according to the manufacturer’s instructions. Tissues were homogenized in a Bead Mill 24 (Fisherbrand) before processing. RNA (1-2 μg) was reverse-transcribed to cDNA using a M-MLV Reverse Transcriptase kit (Invitrogen) following the manufacturer’s instructions. Quantitative real-time PCR was conducted using Perfecta qPCR Fastmix II (QuantaBio) on QuantStudio 7 Pro. The relative transcriptional level of target genes was calculated by the 2-ΔΔCT method with TATA-binding protein (TBP) as housekeeping gene using Design & Analysis Software version 2.7.0. Gene targets with CT values below 38 were considered as not expressed. Taqman probes are listed in TABLE 2. Flow cytometry: Flow cytometry staining for PD-L2 was performed as described elsewhere (Chaib et al., bioRxiv, 2022.2011.2004). Briefly, HUVEC and HUVEC-PD- L2KO cells were harvested in PBS with 10 mM EDTA at 37ºC. The collected cells were stained with yellow live / dead dye solution (Invitrogen) for 15 minutes at 4ºC and washed. Cells were then stained with anti-PD-L2-APCVio770 (#130-105-829, Miltenyi Biotec) diluted 1:11, or isotype control antibody IgG1-APC-Vio770 (#130-113-197, Miltenyi Biotec) diluted 1:50, in FACS buffer (0.5% BSA, 2 mM EDTA in PBS) for 15 minutes. After repeated washes, cells were filtered using a 70 μm cell strainer and analyzed on FACS Canto X, and the median fluorescent intensity was analyzed using FlowJo version 10.7.2. SAβG assay: Cellular SAβG activity was assayed in control and senescent cells. Cells were washed three times with PBS and fixed for 5 minutes in 2% paraformaldehyde (Sigma-Aldrich) and 0.25% glutaraldehyde (Sigma-Aldrich). Thereafter, cells were washed three times with PBS and incubated at 37°C in SAβG staining solution (1 mg / mL of X-gal, 40 mM citric acid / sodium phosphate at pH 6.0, 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 150 mM NaCl, and 2 mM MgCl2) for 16-18 hours, followed by washing with PBS and image capture with an EVOS M5000 microscope imaging system (Invitrogen). Genomic editing: Gene editing was performed as described elsewhere (Chaib et al., supra). Briefly, for lentiviral production, HEK293T cells were infected with Attorney Docket No.07039-2219WO1 2023-151 packaging and envelope plasmids psPAX2 and pMD2.G (#12260 and #12259, Addgene) and either lenti-luciferase-P2A-Neo plasmid (#105621, Addgene) to monitor in vivo bioluminescence or lentiCRISPRv2 (#52961, Addgene) containing sgRNAs to generate bulk PD-L2 knockouts. sgRNAs that were used are listed in TABLE 2. Virus batches were harvested after 48, 72, and 96 hours, centrifuged and filtered. Supernatants were snap-frozen and used with 8 μg / ml polybrene (Sigma Aldrich). Recipient cells were incubated for eight hours with lentiviruses containing media and selected three days later with G418 (#10131035, Gibco) or puromycin (#A1113802, Gibco). Gene editing of the PD-L2 locus was confirmed by sequencing exon 3 of the PD-L2 gene. Primers are listed in TABLE 2, with analysis using SnapGene version 7.0.2. Thereafter, cells were used for the experiments described herein. Conditioned media: 0.15x106cells that were rendered senescent or 0.15x106cells proliferating cells were plated in 6-well plates. After 24 hours, media were replaced with serum free media and cells were incubated for a further 24 hours. Thereafter, media were spun at 500xg, and filtered using a 0.45 μm filter, and stored at -80°C for further analysis. Conditioned media from preadipocytes were prepared by culturing cells in RMPI 1640 containing 1 mM sodium pyruvate, 2 mM glutamine, MEM (minimum essential medium) vitamins, MEM nonessential amino acids, and antibiotics (all Gibco) as described elsewhere (Xu et al., Proc Natl Acad Sci USA, 112:E6301-6310, 2015). Human idiopathic pulmonary fibrosis samples: For post hoc analysis intermittent Dasatinib (100 mg / day) plus Quercetin (1250 mg / day) were orally administered over three consecutive days for three weeks as described elsewhere (Justice et al., EBioMedicine, 40:554-563, 2019). Deidentified samples were used to assay sPD-L2 and sPD-L1 plasma concentrations. Protein analyses in conditioned media and plasma: sPD-L2 (#EPX01A-12215- 901, Invitrogen) and sPD-L1 (#EPX01A-12212-901, Invitrogen) were quantified in conditioned media experiments, in plasma samples obtained from obese and leaner subjects and from IPF patients, using the human basic kit (#EPX010-10420-901, Invitrogen) following the manufacturer’s instructions. For analyzing plasma obtained from younger and older subjects, sPD-L2 and sPD-L1 (both #FCSTM24, R&D Attorney Docket No.07039-2219WO1 2023-151 Systems / Bio-Techne) concentrations were assessed following the manufacturer’s instructions. All multiplex assays were run on a Luminex Flexmap 3D Instrument System (Invitrogen). Protein analyses in conditioned media and plasma samples were performed in duplicate except for plasma analyses in younger and older subjects, which were performed in single samples. Results below the detection range were excluded from further analysis. Human adipose tissue samples and blood samples: Plasma samples were collected from gastric bypass surgery or kidney donors and used to assess sPD-L2 and sPD-L1 levels in obese and leaner subjects. Subject demographics are listed in TABLE 3. Adipose tissue biopsies and plasma samples that were used to assess PD-L2 / sPD-L2 / 1 in younger and older subjects were collected from participants as part of a clinical trial. Subject demographics are listed in TABLE 3. Younger (20-35 years) and older (65-85 years) healthy, weight-stable adults were recruited from the local community. Participants with known chronic disease, including anemia, diabetes, cardiovascular disease, impaired coagulation, liver disease, renal disease, and untreated thyroid disease were excluded. Pregnant or breastfeeding females and participants taking any medication that may have influenced the outcomes or increased the risks of the study also were excluded. Participants were non-smokers and non-tobacco-users, and did not report any alcohol or substance abuse disorders. Following an overnight fast, blood samples were collected from an antecubital vein. Plasma samples were isolated from blood collected in EDTA tubes and centrifuged at 2,000 rpm. Subcutaneous adipose tissue biopsies were collected from the lower abdomen by small-needle liposuction following an overnight fast. Biopsies were performed with local anesthesia (1% lidocaine) and under sterile conditions (Tchoukalova et al., Am J Clin Nutr, 87:56-63, 2008). Adipose tissue was immediately transferred to a mesh strain, rinsed with 0.9% sodium chloride, and cleared of blood clots and connective tissue. Approximately 350 mg of cleared adipose tissue were fixed in 10% zinc formalin for 24 hours under gentle agitation and protection from light. After 24 hours, samples were transferred to 1% formalin and were paraffin- embedded (Kunz et al., Am J Physiol Endocrinol Metab, 321:E105-E121, 2021). Attorney Docket No.07039-2219WO1 2023-151 PD-L2 immunohistochemistry: IHC staining was performed using a Leica Bond RX stainer (Leica). FFPE tissues were sectioned at 5 microns and IHC staining was performed on-line. Slides for anti-PD-L2 staining were retrieved for 20 minutes using Epitope Retrieval 2 (EDTA; Leica) and incubated in Protein Block (Dako) for 5 minutes. The anti-PD-L2 primary antibody (Clone: 366C-9E5; Sigma / Millipore) was diluted to 1:900 in Background Reducing Diluent (Dako) and incubated on the slides for 15 minutes. The detection system used was a Polymer Refine Detection System (Leica). This system includes a hydrogen peroxidase block, post primary and polymer reagent, DAB, and Hematoxylin. Immunostaining visualization was achieved by incubating slides for 10 minutes in DAB and DAB buffer (1:19 mixture) from the Bond Polymer Refine Detection System. To this point, slides were rinsed between steps with 1X Bond Wash Buffer (Leica). Slides were counterstained for five minutes using Schmidt hematoxylin (not the hematoxylin provided with the Refine kit) and molecular biology grade water (1:1 mixture), followed by several rinses in 1X Bond wash buffer and distilled water. Once the immunochemistry process was completed, slides were removed from the stain and rinsed in tap water for 5 minutes. Slides were dehydrated with increasing concentrations of ethyl alcohol and cleared in 3 changes of xylene prior to permanent coverslipping in xylene-based medium. Slides were scanned using MoticEasyScan and positive staining was quantified using QuPath version 0.3.1. Pathological assessment of PD-L2WT and PD-L2KO mice: At 4 or 26 months of age, PD-L2WT and PD-L2KO mice were euthanized, and tissues were either flash frozen for RNA extraction or preserved in 4% paraformaldehyde (PFA; Santa Cruz Biotechnology) for pathological examination. The fixed tissues were processed conventionally, embedded in paraffin, sectioned at 5 microns, and stained with hematoxylin-eosin. The diagnosis of each histopathological change was made with histological classifications in aging mice as described elsewhere (Bronson and Lipman, Growth Dev Aging, 55:169-184, 1991; and Ikeno et al., J Gerontol A Biol Sci Med Sci, 60:1510-1517, 2005). A list of pathological lesions was constructed for each mouse that included both neoplastic and non-neoplastic diseases. Based on these histopathological data, tumor burden, disease burden, and severity of each lesion in each mouse were Attorney Docket No.07039-2219WO1 2023-151 assessed as described elsewhere (Ikeno et al., supra; Ikeno et al., J Gerontol A Biol Sci Med Sci, 58:291-296, 2003; Ikeno et al., J Gerontol A Biol Sci Med Sci, 64:522-529, 2009; and Perez et al., J Gerontol A Biol Sci Med Sci, 66:1286-1299, 2011). Metabolic assessment: PD-L2WT and PD-L2KO mice were fasted for 6 hours (GTT) or 4 hours (ITT). Mice were then injected interperitoneally with 1.5 g / kg glucose (Sigma-Aldrich) or 0.6 U / kg insulin (Novolin R; Novo Nordisk). Blood samples were taken by tail nick at baseline and the indicated time points, and glucose levels were measured using a handheld glucometer (AlphaTrak II, Zoetis). Results were normalized to baseline glucose levels. Therapeutic anti-PD-L2 treatment: ITT was performed at baseline in 22-month- old male mice and allocated to the IgG (#I-536, Leinco Technologies) or anti-PD-L2 (#P379, Leinco Technologies) treatment groups to ensure similar distributions of insulin resistance. Mice received either 100 μg IgG or anti-PD-L2 antibodies every other day for a total of six injections by intraperitoneal injection.26 days after the last antibody injection, insulin sensitivity was reassessed by ITT. Physical fitness: Forelimb grip strength (Newtons) was determined using a grip strength meter (Ametek). Results were averaged from three trials. Transplantation studies: Ear fibroblasts were isolated from 22-month-old C57BL / 6 mice (NIA) obtained from the National Institute on Aging. Cells were then sequentially infected with lentiviruses integrating a luciferase reporter and lentiCRISPRv2 sgRNA-ctrl or sgRNA-PD-L2 to target exon 3 of the mouse PD-L2 gene. Either 0.5x106control cells or doxorubicin-induced senescent cells were then transplanted subcutaneously into the same mice from which they originated. Senescent or control cells were collected by trypsinization. Cell pellets were washed and resuspended in PBS for transplantation. Mice were anesthetized using isoflurane and cells were injected subcutaneously in 50 µl PBS through a 22-G needle as described elsewhere (Xu et al., Nat Med, 24:1246-1256, 2018). The next day, bioluminescence measurements of transplanted cells were performed to establish a baseline measurement, followed by measurement at days 14 and 31 post transplantation. Attorney Docket No.07039-2219WO1 2023-151 Bioluminescence imaging: Mice were anesthetized using isoflurane, their backs were shaved, and they injected intraperitoneally with 150 mg luciferin / kg bodyweight (Perkin Elmer) in PBS. Bioluminescence images were acquired using an IVIS Spectrum in vivo imaging system (Caliper Life Sciences) according to the manufacturer’s instructions. Analysis was performed using Living Image version 4.5.2. Statistical analysis: GraphPad Prism version 10.0.3 was used for statistical analyses. Results are presented as mean ± SD or SEM as stated in the figure descriptions. P< 0.05 was considered to be statistically significant, and exact P values are presented in the figures. Protein analyses in plasma in younger and older subjects were corrected for outliers using the ROUT method with Q = 0.1 %. Kaplan-Meier survival curves were analyzed using Log-rank (Mantel-Cox) test. Statistical tests included Welch’s t test to compare two groups, one-way ANOVA to compare more than two groups of the indicated pairs in the figures, or 2-way ANOVA to compare more than two groups over time as detailed in the figure descriptions. TABLE 2: Taqman probes and primers Human Taqman Probes r*r Attorney Docket No.07039-2219WO1 2023-151 Ccl2 Mm00441242_m1 TFS Ccl5 Mm01302427_m1 TFS rr Attorney Docket No.07039-2219WO1 2023-151 TABLE 3: Demographics of human subjects sPD-Ls in plasma samples from obese and leaner subjects L Results Primary senescent cells upregulate PD-L2 through NF-κB To gain an understanding about links between PD-L2 and cellular senescence, PD-L2 and PD-L1 expression was assessed in several primary human cell types: preadipocytes, umbilical vein endothelial cells (HUVECs), and kidney endothelial cells (HRGEC). Different inducers of cellular senescence, including irradiation, doxorubicin, or replicative stress induced by serial passaging, were tested in these cells. Induction of cellular senescence was confirmed by testing for proliferative arrest, transcriptional upregulation of p16Ink4a, p21CIP1, and SASP factors, and increased senescence-associated β-galactosidase (SAβG) activity (FIGS.15A-15D). PD-L2 was significantly upregulated across all conditions tested, regardless of cell type and senescence inducers (FIGS.16A- 16E). On the other hand, PD-L1 expression was upregulated in senescent human preadipocytes but tended to be down regulated in other senescent cell types, such as HRGEC (FIGS.16A-16E). To determine if transcriptional upregulation leads to increased levels of PD-L2 protein on the cell membrane of senescent cells, flow Attorney Docket No.07039-2219WO1 2023-151 cytometry analyses of HUVECs and CRISPR-Cas9-engineered HUVEC-PD-L2 knockout cells (HUVEC-PD-L2KO) was conducted (FIGS.15E and 16F). Following senescence induction by either doxorubicin or x-ray irradiation, PD-L2 was significantly enriched on the cell membrane of senescent cells, in line with the transcriptional upregulation that was observed, and PD-L2 was not detectible in HUVEC-PD-L2KO cells (FIG.16F). Senescent cancer cells drive PD-L2 expression through tumor necrosis factor alpha (TNF-α) -induced activation of NF-κB, which also constitutes a fundamental driver of the SASP in non-cancerous senescent cells (Chaib et al., bioRxiv, 2022.2011.2004.501681, 2022; and Tilstra et al., J Clin Invest, 122:2601-2612, 2012). To ascertain if PD-L2 is regulated in a similar manner in normal primary cells, non- senescent HUVECs were treated with TNF-α, a potent activator of the NF-κB pathway (FIG.15F). TNF-α treatment induced predominantly PD-L2 (fold change: 4.8) and to a lesser extent PD-L1 (fold change: 2.2) mRNA expression in HUVECs (FIG.16G). Conversely, inhibiting the NF-κB pathway with the I-kappa-B Kinase (IκK) inhibitor BAY 11-7082 blocked TNF-α-induced PD-L2 expression, as well as expression of other NF-κB target genes, including C-C motif chemokine ligand 5 (CCL5) (FIG.16G). To confirm that PD-L2 expression is regulated through the NF-κB pathway in cellular senescence, the NF-κB pathway was blocked in pre-senescent (day 3) and fully senescent (day 10) HUVECs (FIGS.15G and 16H). PD-L2 and CCL5 mRNA expression was abolished in both pre-senescent or fully senescent cells by the IκK inhibitor, suggesting that the NF-κB pathway is a major driver of senescence-associated PD-L2 expression (FIGS.15G and 16H). Activation of the JAnus Kinase (JAK)-Signal Transducer and Activator of Transcription (STAT) pathway is another driver of many SASP components, and can be activated by interferon‐gamma (IFN‐γ) (Xu et al., Proc Natl Acad Sci USA, 112:E6301-6310, 2015; and Hu and Ivashkiv, Immunity, 31:539-550, 2009). Activating the JAK-STAT pathway by IFN‐γ led to induction of both PD-L2 and PD-L1 expression, suggesting a shared regulatory node that controls these immune checkpoint inhibitors (FIG.15H). This was consistent with work described elsewhere showing that elevated PD-L1 expression levels are mediated by the JAK-STAT pathway in HRasV12-induced Attorney Docket No.07039-2219WO1 2023-151 senescent IMR90 cells, and with work showing that both PD-L2 and PD-L1 can be upregulated through interferon receptor signaling (Onorati et al., Mol Cell Biol, 42:e0017122, 2022; and Garcia-Diaz et al., Cell Rep, 19:1189-1201, 2017). RT-qPCR- determined levels of senescence and SASP markers in control and irradiation-induced senescent HUVECs and HUVEC-PD-L2KO cells assayed after 10 days also are shown in FIG.15I, while representative images showing SAβG of control and irradiation- or doxorubicin-induced senescent HUVEC and HUVEC-PD-L2KO cells (assayed after 14 days) are shown in FIG.15J. These studies indicated that PD-L2 is not important for the development of cellular senescence, as PD-L2WT and PD-L2KO cells developed an indistinguishable senescence phenotype. Taken together, these results indicated that PD-L2 expression is differentially upregulated through the NF-κB pathway in cellular senescence across a variety of senescent primary cells, irrespective of the inducer of senescence. Senescent cells release sPD-L2 and senolytics target PD-L2 highly expressing cells Senescent cells can express MMPs as core components of the SASP, thereby remodeling their extracellular microenvironment and modulating cell membrane composition through the proteolytic shedding of receptors and ligands (Coppe et al., Annu Rev Pathol, 5:99-118, 2010). Cell membrane bound PD-L2 and PD-L1 are sensitive to proteolytic cleavage by MMPs, releasing their extracellular domain from the cell membrane. Whereas PD-L1 seems to be selectively cleaved by MMP13, PD-L2 can be cleaved by MMP2 and MMP9, among others (Dezutter-Dambuyant, et al., Oncoimmunology, 5:e1091146, 2016). Given the increased expression of various MMPs in senescent cells, studies were conducted to determine whether if PD-L2 is released by senescent cells. Senescent HUVECs exhibited increased MMP2 and MMP9 expression with doxorubicin-induced senescence, and senescent human preadipocytes had increased MMP2 expression, whereas expression of MMP13, which selectively cleaves PD-L1, was not detected (FIGS.17A and 18A-18B). Next, conditioned media from HUVECs and HUVEC-PD-L2KO cells were assessed. Soluble PD-L2 (sPD-L2) was detected but Attorney Docket No.07039-2219WO1 2023-151 sPD-L1 was not (below the detection limit of 3.29 pg / mL), and consistent with the absence of PD-L2 on the cell membrane, HUVEC-PD-L2KO cells did not release sPD- L2 (at least above the detection limit of 46.21 pg / mL) (FIGS.16F and 18C). Moreover, when conditioned media from senescent preadipocytes was assessed following serial passaging, a significant increase in sPD-L2 was observed (FIG.18D). Also of note, preadipocyte sPD-L1 was not detected (detection limit 3.29 pg / mL) (FIG.18D). To determine whether sPD-L2 is cleaved from the cell membrane through MMPs, senescent HUVEC cells were treated with Ilomastat, a broad spectrum MMP inhibitor (MMPi) (Vandenbroucke and Libert, Nat Rev Drug Discov, 13:904-927, 2014). Senescent HUVECs released significantly more sPD-L2 into conditioned media compared to control cells (FIG.17B). Pretreatment of senescent cells with MMPi resulted in reduced sPD-L2 levels, suggesting that sPD-L2 secretion is partially mediated through proteolytic cleavage of the PD-L2 extracellular domain by MMPs (FIG.17B). In comparison, sPD- L1 was not detected, possibly due to the lack or low levels of MMP13 expression in the cell types examined (FIGS.18A, 18B, and 18E). While MMP2 and MMP9 can be expressed by various cell types, the expression of MMP13 seem to be more restricted, with expression usually observed in cartilage, bone, chondrocytes, and cancer cells (see, e.g., proteinatlas.org; Uhlen et al., Science, 347:1260419, 2015; Vincenti and Brinckerhoff, Arthritis Res, 4:157-164, 2002; and Li et al., Cancers (Basel), 14, 2022). Next, sPD-L2 expression was assessed in vivo in clinical settings linked to senescent cell accumulation: aging and obesity (Lopez-Otin et al., Cell, 186:243-278, 2023; Palmer et al., Aging Cell, 18:e12950, 2019; and Tchkonia et al., J Clin Endocrinol Metab, 106:e1481-e1487, 2021). Blood plasma samples from older (71.5±4.4 years) or obese (BMI: 43.2±8.0 kg / m2) subjects had significantly more sPD-L2 compared to younger (27.1±4.0 years) or leaner (BMI: 27.2±3.2 kg / m2) people (FIGS.17C-17D and 18F, and TABLE 3). In contrast, sPD-L1 appeared to be significantly elevated with aging but not in obesity (FIGS.17C-17D). Surprisingly, steady state blood plasma levels of sPD-L2 were 7-fold higher than sPD-L1 in young subjects (sPD-L2: 419.87 pg / mL vs. sPD-L1: 60.28 pg / mL). Due to its low abundance, sPD-L1 was not detected in all samples (detection limit 3.29 pg / mL) (FIG.17C), consistent with work described Attorney Docket No.07039-2219WO1 2023-151 elsewhere showing that older subjects have elevated TNF-α signaling and MMP activity, which could further prompt sPD-L2 release (Davizon-Castillo et al., Blood, 134:727-740, 2019; Yu et al., BMC Musculoskelet Disord, 14:2, 2013; and McNulty et al., Am J Hypertens, 18:504-509, 2005). Further studies were conducted to determine if pharmacological elimination of senescent cells would reduce the abundance of PD-L2 expressing cells. Senescent human preadipocytes or human adipose tissue explants were treated with a senolytic cocktail consisting of Dasatinib plus Quercetin (D+Q), which typically eliminates about 50% of senescent cells in vitro (Zhu et al., Aging Cell, 14:644-658, 2015). PD-L2 expression was assessed in the senolytic resistant cells (surviving fraction) remaining after D+Q treatment. After senolytic treatment, the treated cultures and tissue explants exhibited reduced levels of PD-L2 (FIGS.17E-17F). In contrast, PD-L1 expression remained largely unchanged after senolytic treatment (FIGS.17E-17F), suggesting that senolytics preferentially target PD-L2 highly-expressing cells. Idiopathic pulmonary fibrosis (IPF) is a lung disease that is linked to senescent cell accumulation and may contribute to disease progression (Schafer et al., Nat Commun, 8:14532, 2017). To determine if senolytics can target PD-L2 expressing cells in vivo, sPD-L2 levels were assayed in samples from the first-in-human, open-label, pilot study of IPF patients receiving the senolytic cocktail D+Q, which had suggested that senolytics may alleviate physical dysfunction in IPF (Justice et al., EBioMedicine, 40:554-563, 2019). The assays demonstrated that senolytic treatment resulted in significant reduction of sPD-L2 levels in plasma from IPF patients who had received D+Q (D:100 mg / day, Q:1250 mg / day, three-days / week over three-weeks), whereas sPD- L1 levels remained unaffected or could not be detected (detection limit 3.29 pg / mL) (FIG.17G). In observational control subjects who did not receive treatment but took part in blood testing, sPD-L2 levels remained unchanged and sPD-L1 could not be detected (FIGS.17G and 18G). Thus, these studies indicated that senescent cells release sPD-L2, and that sPD-L2 levels are associated with senescent cell burden. Further, PD-L2 highly-expressing cells Attorney Docket No.07039-2219WO1 2023-151 appeared to be targeted by senolytics, resulting in decreased circulating sPD-L2 levels in plasma post-senolytic therapy. PD-L2KO mice have reduced senescent cell burden Senescent cells can be detrimental to metabolic health and physical fitness, and elimination of senescent cells can prevent or alleviate disease and age-related dysfunction (Chaib et al., Nat Med, 28:1556-1568, 2022; Palmer et al., Aging Cell, 18:e12950, 2019; Xu et al., Nat Med, 24:1246-1256, 2018; Kirkland and Tchkonia, EBioMedicine, 21:21- 28, 2017; Kirkland and Tchkonia, J Intern Med, 288:518-536, 2020; and Tchkonia and Kirkland, JAMA, 320:1319-1320, 2018). PD-L2 knock out (PD-L2KO) mice are viable and fertile. The continuous lack of PD-L2 did not lead to significant differences in survival between PD-L2KO and PD-L2WT male and female mice, at least until 26 months of age (FIG.19A). Aged mice expressed more PD-L2 in peripheral metabolic tissues such as liver, skeletal muscle, and adipose tissue (FIGS.20A-20B). While PD-L2 was primarily upregulated with aging in liver and adipose tissue in male mice, older female mice had elevated PD-L2 in skeletal muscle and adipose tissue, suggesting sex- based differences (FIGS.20A-20B). In contrast, PD-L1 was only significantly upregulated in the liver of aged male mice (FIGS.20A-20B). This increase in PD-L2 expression was also seen in adipose tissue from older human subjects who had increased senescent cell burden (FIGS.20C-20D) (Palmer et al., Aging Cell, 18:e12950, 2019; and Tchkonia et al., Aging Cell, 9:667-684, 2010). Adipose tissue biopsies evaluated by immunohistochemistry from older vs. younger subjects (73.0 vs.28.1 years, respectively) had elevated PD-L2 expression (FIG.20C). PD-L2 is required for senescent cell persistence after senescence induction in cancer cells by chemotherapy (Chaib et al., bioRxiv, 2022.2011.2004.501681, 2022). To determine if the lack of PD-L2 also affects senescent cell burden with aging, senescent cell burden was assessed in 26 month-old wild-type (WT) and PD-L2KO mice. Strikingly, in livers of old male PD-L2KO mice, senescent cell marker expression was substantially reduced, as indicated by levels of p16Ink4aand multiple SASP markers, including Tnf-α, Ccl5, Mmp9, Oas2, and Oas3 (FIG.20D). Similarly, in skeletal muscle Attorney Docket No.07039-2219WO1 2023-151 of old PD-L2KO female mice, markers of senescence including p16Ink4a, p21Cip1, and the SASP factors Ccl2 and Mmp3 were reduced (FIG.20E). Given the propensity of PD-1 knockout mice to develop autoimmune disorders by 14 months of age and the occurrence of autoimmune related inflammatory adverse events in cancer patients receiving anti-PD- 1 or anti-PD-L1 therapy (Tysoe Nat Rev Endocrinol, 18:334, 2022; Nishimura et al., Immunity, 11:141-151, 1999; and Martins et al., Nat Rev Clin Oncol, 16:563-580, 2019), inflammatory features were compared in tissues of young and old PD-L2WT and PD- L2KO mice. Histopathological scoring of harvested tissues (heart, brain, kidney, liver, spleen, lung, pancreas, skeletal muscle, skin, adipose tissue) revealed that the old PD- L2KO mice did not have substantially increased inflammation vs. PD-L2WT mice, nor did the PD-L2KO mice have statistically significant differences from PD-L2WT mice in disease or tumor burden (FIGS.19B-19E and 20G). Taken together, these studies demonstrated that PD-L2KO mice accumulate fewer senescent cells and have less pronounced SASP factor expression with aging than their WT counterparts. Moreover, mice that lack PD-L2 do not differ in disease burden or inflammation at 26 months of age compared to wild type mice. Blocking effects of PD-L2 alleviates age-related dysfunction and accelerates senescent cell clearance Aging and senescent cell accumulation are associated with declines in physical fitness and metabolic health, characterized by increased insulin resistance and a higher risk of developing metabolic disorders such as type 2 diabetes, at least in part through the SASP (Xu et al., Nat Med, 24:1246-1256, 2018; and Xu et al., Elife, 4:e12997, 2015). The reduction in senescent cells within key metabolic tissues (e.g., liver, skeletal muscle, and adipose tissue) observed in the studies described herein may be of particular significance, as metabolic processes often become perturbed with aging, manifested by development of insulin resistance, especially in male mice (Macotela et al., Diabetes, 58:803-812, 2009). Considering the importance of metabolic health in the context of healthy aging, studies were conducted in aged PD-L2WT and PD-L2KO mice to gauge their response to glucose and insulin challenges. These studies revealed a trend toward Attorney Docket No.07039-2219WO1 2023-151 improved glucose tolerance and a significant enhancement in insulin sensitivity among 24 month-old male PD-L2KO mice (FIGS.21A-21C). These differences in GTT and ITT were not observed in young PD-L2WT and PD-L2KO mice, which did not have much (if any) senescent cell accumulation (FIGS.20D-20E and 21D-21F). Old female PD-L2KO mice did not have improved glucose tolerance or insulin sensitivity at 24 months of age, indicating that both genotypes remained responsive to glucose and insulin at that age (FIGS.22A-22C). To explore the therapeutic potential of anti-PD-L2 intervention to increase insulin sensitivity, old mice matched for insulin resistance received either six injections of IgG or anti-PD-L2 for two weeks. After a recovery period of one month, insulin sensitivity was reassessed (FIG.21G). Consistent with the genetic PD-L2KO model, anti-PD-L2 therapy restored insulin sensitivity in aged mice (FIGS.21C and 21H). Given the induction of PD-L2 and high levels of indicators of cellular senescence in skeletal muscle of old female mice (FIG.20F), grip strength was assessed in old female PD-L2WT and PD-L2KO mice. At 22 months of age, female PD-L2KO mice had improved grip strength, whereas male mice did not (FIGS.21I and 22D). Thus, PD-L2 upregulation with aging contributed to sex-dependent alleviation of age-related tissue dysfunction. To further understand the role of PD-L2 during aging, an autologous transplantation model of control and doxorubicin induced senescent mouse ear fibroblasts was used (Xu et al., Nat Med, 24:1246-1256, 2018). PD-L2 was higher in the transplanted senescent fibroblasts than in control ear fibroblasts (FIG.22E). Isolated ear fibroblasts were infected with lentiviruses integrating a luciferase reporter and either CRISPR-Cas9 sgControl (WT) or sgPD-L2 (PD-L2KO) to block PD-L2 function (FIGS. 21J and 22F). p16Ink4aand p21Cip1were similar in control and senescent WT and PD- L2KO cells, indicating that PD-L2 did not have an intrinsic effect on cells undergoing cellular senescence (FIG.22G). These cells were transplanted subcutaneously into 23 month-old immunocompetent mice, and survival of the transplanted cells was measured in vivo using a bioluminescence imaging system (FIG.21J). Remarkably, by 31 days after transplantation, a substantial portion of senescent PD-L2KO cells had been eliminated as compared to their senescent WT counterparts (FIGS.21K and 21L), while Attorney Docket No.07039-2219WO1 2023-151 senescent WT cells persisted equally to control cells, consistent with the possibility that PD-L2 is relevant for senescent cell persistence in vivo. Thus, these studies demonstrated that interventions to block PD-L2 function can restore metabolic health and physical fitness in old mice, and that that blocking PD-L2 leads to accelerated clearance of transplanted senescent cells. OTHER EMBODIMENTS It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

Claims

Attorney Docket No.07039-2219WO1 2023-151 WHAT IS CLAIMED IS:

1. A method for classifying a mammal as having, or being likely to have, a senescence-related disease or condition, wherein said method comprises: detecting an elevated level of a secreted programmed cell death 1 ligand 2 (PD- L2) polypeptide in a biological fluid sample obtained from a mammal, and classifying said mammal as having said senescence-related disease or condition.

2. The method of claim 1, wherein said mammal is a human.

3. The method of claim 1 or claim 2, wherein said senescence-related disease or condition is a senescence-related cancer.

4. The method of claim 3, wherein said senescence-related cancer is a melanoma, a pancreatic adenocarcinoma, an osteosarcoma, a squamous cell carcinoma, a breast cancer, or a head and neck squamous cell carcinoma.

5. The method of claim 1 or claim 2, wherein said senescence-related disease or condition is selected from the group consisting of cardiovascular diseases, neurodegenerative diseases, pulmonary diseases, chronic inflammatory diseases, liver diseases, kidney diseases, eye diseases, skin diseases, vascular diseases, musculoskeletal disorders, metabolic disorder, immune system dysfunction, osteoarthritis, type 2 diabetes, and age-related hearing loss.

6. The method of claim 1, wherein said biological fluid sample comprises whole blood, plasma, or serum.

7. The method of claim 1, wherein said elevated level of said secreted PD-L2 polypeptide is as compared to a reference level of said secreted PD-L2 polypeptide present in biological fluid samples from controls known not to have said senescence- related disease or condition.

8. The method of claim 1, wherein said detecting comprises using an anti-PD-L2 antibody to detect said elevated level of said secreted PD-L2 polypeptide.Attorney Docket No.07039-2219WO1 2023-151 9. A method for treating a mammal having a senescence-related disease or condition, wherein said method comprises: (a) identifying said mammal as having a biological fluid sample comprising the presence of an elevated level of secreted PD-L2; and (b) administering to said mammal a treatment for said senescence-related disease or condition.

10. The method of claim 9, wherein said mammal is a human.

11. The method of claim 9 or claim 10, wherein said senescence-related disease or condition is a senescence-related cancer.

12. The method of claim 11, wherein said senescence-related cancer is a melanoma, a pancreatic adenocarcinoma, an osteosarcoma, a squamous cell carcinoma, a breast cancer, or a head and neck squamous cell carcinoma.

13. The method of claim 9 or claim 10, wherein said senescence-related disease or condition is selected from the group consisting of cardiovascular diseases, neurodegenerative diseases, pulmonary diseases, chronic inflammatory diseases, liver diseases, kidney diseases, eye diseases, skin diseases, vascular diseases, musculoskeletal disorders, metabolic disorder, immune system dysfunction, osteoarthritis, type 2 diabetes, and age-related hearing loss.

14. The method of claim 9, wherein said biological fluid sample comprises whole blood, plasma, or serum.

15. The method of claim 9, wherein said elevated level of secreted PD-L2 is as compared to a reference level present in controls known not to have said senescence- related disease or condition.

16. The method of claim 9, wherein said identifying comprises using an anti-PD-L2 antibody to detect said elevated level of said secreted PD-L2 polypeptide in said sample.Attorney Docket No.07039-2219WO1 2023-151 17. The method of claim 9, wherein said treatment comprises an anti-PD-L2 agent, a senolytic agent, an anti-tumor necrosis factor alpha (TNFα) agent, an NF-κB inhibitor, a matrix metalloprotease (MMP) inhibitor, a gamma secretase inhibitor, or any combination thereof.

18. A method for treating a mammal having a senescence-related disease or condition, wherein said method comprises administering, to a mammal identified as having a biological fluid sample comprising the presence of an elevated level of secreted PD-L2, a treatment for said senescence-related disease or condition.

19. The method of claim 18, wherein said mammal is a human.

20. The method of claim 18 or claim 19, wherein said senescence-related disease or condition is a senescence-related cancer.

21. The method of claim 20, wherein said senescence-related cancer is a melanoma, a pancreatic adenocarcinoma, an osteosarcoma, a squamous cell carcinoma, a breast cancer, or a head and neck squamous cell carcinoma.

22. The method of claim 18 or claim 19, wherein said senescence-related disease or condition is selected from the group consisting of cardiovascular diseases, neurodegenerative diseases, pulmonary diseases, chronic inflammatory diseases, liver diseases, kidney diseases, eye diseases, skin diseases, vascular diseases, musculoskeletal disorders, metabolic disorder, immune system dysfunction, osteoarthritis, type 2 diabetes, and age-related hearing loss.

23. The method of claim 18, wherein said biological fluid sample comprises whole blood, plasma, or serum.

24. The method of claim 18, wherein said elevated level of secreted PD-L2 is as compared to a reference level present in controls known not to have said cancer.Attorney Docket No.07039-2219WO1 2023-151 25. The method of claim 18, wherein said mammal was identified as having an elevated level of PD-L2 polypeptide in said biological fluid sample by using an anti-PD- L2 antibody to detect said elevated level of said secreted PD-L2 polypeptide.

26. The method of claim 18, wherein said treatment comprises an anti-PD-L2 agent, a senolytic agent, an anti-TNFα agent, an NF-κB inhibitor, a MMP inhibitor, a gamma secretase inhibitor, or any combination thereof.

27. A method for assessing the efficacy of a treatment in a mammal having a senescence-related disease or condition, wherein said method comprises: determining a first level of PD-L2 in a first biological sample obtained from said mammal prior to administration of said treatment; administering said treatment to said mammal; determining a second level of PD-L2 in a second biological sample obtained from said mammal after administration of said treatment; and when said second level of PD-L2 is lower than said first level of PD-L2, determining that said treatment is effective, or when said second level of PD-L2 is not lower than said first level of PD-L2, determining that said treatment is not effective.

28. The method of claim 27, wherein said mammal is a human.

29. The method of claim 27 or claim 28, wherein said senescence-related disease or condition is a senescence-related cancer.

30. The method of claim 29, wherein said senescence-related cancer is a melanoma, a pancreatic adenocarcinoma, an osteosarcoma, a squamous cell carcinoma, a breast cancer, or a head and neck squamous cell carcinoma.

31. The method of claim 27 or claim 28, wherein said senescence-related disease or condition is selected from the group consisting of cardiovascular diseases, neurodegenerative diseases, pulmonary diseases, chronic inflammatory diseases, liver diseases, kidney diseases, eye diseases, skin diseases, vascular diseases, musculoskeletalAttorney Docket No.07039-2219WO1 2023-151 disorders, metabolic disorder, immune system dysfunction, osteoarthritis, type 2 diabetes, and age-related hearing loss.

32. The method of claim 27, wherein said first and second biological samples are biological fluid samples, and wherein said PD-L2 is a secreted PD-L2 polypeptide.

33. The method of claim 32, wherein said first and second biological fluid samples comprise whole blood, plasma, or serum.

34. The method of claim 32 or claim 33, wherein said determining comprises detecting a level of secreted PD-L2 polypeptide in said first and second biological fluid samples.

35. The method of claim 27, wherein said elevated level of PD-L2 is as compared to a reference level present in controls known not to have said senescence-related disease or condition.

36. The method of claim 27, wherein said treatment comprises an anti-PD-L2 agent, a senolytic agent, an anti-TNFα agent, an NF-κB inhibitor, a MMP inhibitor, a gamma secretase inhibitor, or any combination thereof.

37. A method for treating a senescence-related disease or condition in a mammal, wherein said method comprises: administering, to a mammal having a senescent-related disease or condition and identified as having a biological sample containing an elevated level of PD-L2, (a) an anti-TNFα therapy, an NF-κB inhibitor, or an anti-TNFα and an NF-κB inhibitor, and (b) an anti-PD-L2 agent.

38. The method of claim 37, wherein said mammal is a human.

39. The method of claim 37 or claim 38, wherein said senescence-related disease or condition is a senescence-related cancer.Attorney Docket No.07039-2219WO1 2023-151 40. The method of claim 39, wherein said senescence-related cancer is a melanoma, a pancreatic adenocarcinoma, an osteosarcoma, a squamous cell carcinoma, a breast cancer, or a head and neck squamous cell carcinoma.

41. The method of claim 37 or claim 38, wherein said senescence-related disease or condition is selected from the group consisting of cardiovascular diseases, neurodegenerative diseases, pulmonary diseases, chronic inflammatory diseases, liver diseases, kidney diseases, eye diseases, skin diseases, vascular diseases, musculoskeletal disorders, metabolic disorder, immune system dysfunction, osteoarthritis, type 2 diabetes, and age-related hearing loss.

42. The method of claim 37, wherein said biological sample is a biological fluid sample, and wherein said PD-L2 is a secreted PD-L2 polypeptide.

43. The method of claim 42, wherein said biological fluid sample comprises whole blood, plasma, or serum.

44. The method of claim 37, wherein said elevated level of PD-L2 is as compared to a reference level present in controls known not to have said senescence-related disease or condition.

45. The method of claim 37, comprising administering said anti-TNFα therapy.

46. The method of claim 45, wherein said anti-TNFα therapy is selected from the group consisting of etanercept, infliximab, adalimumab, certolizumab pegol, and golimumab.

47. The method of claim 37, comprising administering said NF-κB inhibitor.

48. The method of claim 47, wherein said NF-κB inhibitor is selected from the group consisting of bortezomib, curcumin, resveratrol, Bay 11-7082, TPCA-1, parthenolide, wedelolactone, celastrol, tanshinone IIA, and thymoquinone.Attorney Docket No.07039-2219WO1 2023-151 49. The method of claim 37, wherein said anti-PD-L2 agent comprises an anti-PD-L2 antibody.

50. A method for treating a senescence-related disease or condition in a mammal, wherein said method comprises: administering, to a mammal having a senescence-related disease or condition and identified as having a biological sample containing an elevated level of PD-L2, (a) an MMP inhibitor, a gamma secretase inhibitor, or an MMP inhibitor and a gamma secretase inhibitor, and (b) an anti-PD-L2 agent, a senolytic agent, or an anti-PD-L2 agent and a senolytic agent.

51. The method of claim 50, wherein said mammal is a human.

52. The method of claim 50 or claim 51, wherein said senescence-related disease or condition is a senescence-related cancer.

53. The method of claim 52, wherein said senescence-related cancer is a melanoma, a pancreatic adenocarcinoma, an osteosarcoma, a squamous cell carcinoma, a breast cancer, or a head and neck squamous cell carcinoma.

54. The method of claim 50 or claim 51, wherein said senescence-related disease or condition is selected from the group consisting of cardiovascular diseases, neurodegenerative diseases, pulmonary diseases, chronic inflammatory diseases, liver diseases, kidney diseases, eye diseases, skin diseases, vascular diseases, musculoskeletal disorders, metabolic disorder, immune system dysfunction, osteoarthritis, type 2 diabetes, and age-related hearing loss.

55. The method of claim 50, wherein said biological sample is a biological fluid sample, and wherein said PD-L2 is a secreted PD-L2 polypeptide.

56. The method of claim 55, wherein said biological fluid sample comprises whole blood, plasma, or serum.Attorney Docket No.07039-2219WO1 2023-151 57. The method of claim 50, wherein said elevated level of PD-L2 is as compared to a reference level present in controls known not to have said senescence-related disease or condition.

58. The method of claim 50, comprising administering said MMP inhibitor.

59. The method of claim 58, wherein said MMP inhibitor is selected from the group consisting of marimastat (BB-2516), batimastat (BB-94), doxycycline, GM6001 (ilomastat), tetracyclines, collagen peptide-derived inhibitors, and tissue inhibitors of metalloproteinases (TIMPs).

60. The method of claim 50, comprising administering said gamma secretase inhibitor.

61. The method of claim 60, wherein said gamma secretase inhibitor is selected from the group consisting of semagacestat (LY450139), avagacestat (BMS-708163), RO4929097, MK-0752 (dibenzazepine), LY-411,575, and E2012 (ELND006).

62. The method of claim 50, comprising administering said anti-PD-L2 agent.

63. The method of claim 62, wherein said anti-PD-L2 agent comprises an anti-PD-L2 antibody.

64. The method of claim 50, comprising administering said senolytic agent.

65. The method of claim 64, wherein said senolytic agent is selected from the group consisting of dasatinib, quercetin, navitoclax, A1331852, A1155463, fisetin, luteolin, geldanamycin, tanespimycin, alvespimycin, piperlongumine, panobinostat, FOX04- related peptides, nutlin3a, ruxolitinib, metformin, rapamycin, JAK1 / 2 inhibitors, NF-κB inhibitors, p38 inhibitors, IL-6 inhibitors, and STAT3 inhibitors.

Citation Information

Patent Citations

  • PD-l2 biomarkers predictive of PD-1 pathway inhibitor responses in esophagogastric cancers

    US20180238884A1

  • Identification and elimination of damaged and / or senescent cells

    US20200123607A1

  • Representative diagnostics

    WO2017079763A1